Method for treating muscle wasting syndrome using antagonist antibodies against GDF-8

ABSTRACT

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. application Ser.No. 13/910,834 filed Jun. 5, 2013, now pending; which is a divisionalapplication of U.S. application Ser. No. 13/693,995 filed Dec. 4, 2012,now issued as U.S. Pat. No. 8,496,934; which is a divisional applicationof U.S. application Ser. No. 13/030,978 filed Feb. 18, 2011, now issuedas U.S. Pat. No. 8,349,327; which is a divisional application of U.S.application Ser. No. 12/508,618 filed Jul. 24, 2009, now issued as U.S.Pat. No. 7,910,107; which is a divisional application of U.S.application Ser. No. 11/503,062 filed Aug. 14, 2006, now issued as U.S.Pat. No. 7,888,486; which claims the benefit under 35 USC § 119(e) toU.S. Application Ser. No. 60/709,704 filed Aug. 19, 2005. The disclosureof each of the prior applications is considered part of and isincorporated by reference in the disclosure of this application.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted via EFS-Web and is hereby incorporated by reference in itsentirety. Said ASCII copy, created on Jan. 21, 2015, is namedPFIZER1250-6_ST25.txt and is 23 KB in size.

BACKGROUND OF THE INVENTION

Field of the Invention

The technical field of the invention relates to growth anddifferentiation factor-8 (GDF-8) antagonists, in particular, antibodiesagainst GDF-8, e.g., mouse, human and humanized antibodies and theirfragments, particularly those that inhibit GDF-8 activity in vitroand/or in vivo. The field further relates to treating, ameliorating,preventing, prognosing, or monitoring GDF-8-associated disorders, e.g.,muscle disorders, neuromuscular disorders, bone degenerative disorders,metabolic or induced bone disorders, adipose disorders, glucosemetabolism disorders or insulin-related disorders, particularlyamyotrophic lateral sclerosis (“ALS”).

Related Background Art

Growth and differentiation factor-8 (GDF-8), also known as myostatin, isa secreted protein and member of the transforming growth factor-beta(TGF-β) superfamily of structurally related growth factors. Members ofthis superfamily possess growth-regulatory and morphogenetic properties(Kingsley et al. (1994) Genes Dev. 8:133-46; Hoodless et al. (1998)Curr. Topics Microbiol. Immunol. 228:235-72). Human GDF-8 is synthesizedas a 375 amino acid precursor protein that forms a homodimer complex.During processing, the amino-terminal propeptide, known as the“latency-associated peptide” (LAP), is cleaved and may remainnoncovalently bound to the homodimer, forming an inactive complexdesignated the “small latent complex” (Miyazono et al. (1988) J. Biol.Chem. 263:6407-15; Wakefield et al. (1988; J. Biol. Chem. 263:7646-54;Brown et al. (1999) Growth Factors 3:35-43; Thies et al. (2001) GrowthFactors 18:251-59; Gentry et al. (1990) Biochemistry 29:6851-57; Deryncket al. (1995) Nature 316:701-05; Massague (1990) Ann. Rev. Cell Biol.12:597-641). Proteins such as follistatin and its relatives also bindmature GDF-8 homodimers and inhibit GDF-8 biological activity (Gamer etal. (1999) Dev. Biol. 208:222-32).

An alignment of the deduced GDF-8 amino acid sequence from variousspecies demonstrates that GDF-8 is highly conserved (McPherron et al.(1997) Proc. Natl. Acad. Sci. U.S.A. 94:12457-61). The sequences ofhuman, mouse, rat, porcine, and chicken GDF-8 are 100% identical in theC-terminal region, while baboon, bovine, and ovine GDF-8 differ by amere 3 amino acids at the C-terminus. The high degree of GDF-8conservation across species suggests that GDF-8 has an essentialphysiological function.

GDF-8 has been shown to play a major role in the regulation of muscledevelopment and homeostasis by inhibiting both proliferation anddifferentiation of myoblasts and satellite cells (Lee and McPherron(1999) Curr. Opin. Genet. Dev. 9:604-07; McCroskery et al. (2003) J.Cell. Biol. 162:1135-47). It is expressed early in developing skeletalmuscle, and continues to be expressed in adult skeletal muscle,preferentially in fast twitch types. Additionally, GDF-8 overexpressedin adult mice results in significant muscle loss (Zimmers et al. (2002)Science 296:1486-88). Also, natural mutations that render the GDF-8 geneinactive have been shown to cause both hypertrophy and hyperplasia inboth animals and humans (Lee and McPherron (1997) supra). For example,GDF-8 knockout transgenic mice are characterized by a marked hypertrophyand hyperplasia of the skeletal muscle and altered cortical bonestructure (McPherron et al. (1997) Nature 387:83-90; Hamrick et al.(2000) Bone 27:343-49). Similar increases in skeletal muscle mass areevident in natural GDF-8 mutations in cattle (Ashmore et al. (1974)Growth 38:501-07; Swatland et al. (1994) J. Anim. Sci. 38:752-57;McPherron et al., supra; Kambadur et al. (1997) Genome Res. 7:910-15).In addition, various studies indicate that increased GDF-8 expression isassociated with HIV-induced muscle wasting (Gonzalez-Cadavid et al.(1998) Proc. Natl. Acad. Sci. U.S.A. 95:14938-43). GDF-8 has also beenimplicated in the production of muscle-specific enzymes (e.g., creatinekinase) and myoblast proliferation (WO 00/43781).

In addition to its growth-regulatory and morphogenetic properties, GDF-8is believed to participate in numerous other physiological processes,including glucose homeostasis during type 2 diabetes development,impaired glucose tolerance, metabolic syndromes (i.e., a syndrome suchas, e.g., syndrome X, involving the simultaneous occurrence of a groupof health conditions, which may include insulin resistance, abdominalobesity, dyslipidemia, hypertension, chronic inflammation, aprothrombotic state, etc., that places a person at high risk for type 2diabetes and/or heart disease), insulin resistance (e.g., resistanceinduced by trauma such as burns or nitrogen imbalance), and adiposetissue disorders (e.g., obesity, dyslipidemia, nonalcoholic fatty liverdisease, etc.) (Kim et al. (2000) Biochem. Biophys. Res. Comm.281:902-06).

A number of human and animal disorders are associated with functionallyimpaired muscle tissue, e.g., amyotrophic lateral sclerosis (“ALS”),muscular dystrophy (“MD”; including Duchenne's muscular dystrophy),muscle atrophy, organ atrophy, frailty, congestive obstructive pulmonarydisease (COPD), sarcopenia, cachexia, and muscle wasting syndromescaused by other diseases and conditions. Currently, few reliable oreffective therapies exist to treat these disorders. The pathology ofthese diseases indicates a potential role for GDF-8 signaling as atarget in the treatment of these diseases.

ALS is a late onset and fatal neurodegenerative disease characterized bydegeneration of the central nervous system and muscle atrophy. ALStypically initiates with abnormalities in gait and loss of dexterity,and then progresses to paralysis of limbs and diaphragm. While mostcases of ALS are sporadic and are of unknown etiology, 5-10% of caseshave been shown to result from dominant familial (FALS) inheritance.Approximately 10-20% of FALS cases are attributed to mutations in theCu/Zn superoxide dismutase (SOD1) gene (reviewed in Bruijn et al. (2004)Ann. Rev. Neurosci. 27:723-49). SOD1 is a heterodimeric metallo-proteinthat catalyzes the reaction of superoxide into hydrogen peroxide anddiatomic oxygen, and as loss of SOD1 does not result in motor neurondisease (Reaume et al. (1996) Nat. Genet. 13:43-47), it is believed toinduce disease by toxic gain of function (reviewed in Bruijn et al.,supra). The specific mechanisms of SOD1-induced neuronal cell death areunclear, and may involve alterations in axonal transport, cellularresponses to misfolded protein, mitochondrial dysfunction, andexcitotoxicity (Bruijn et al., supra).

The degeneration of motor neurons observed in ALS may occur via multiplemechanisms, including uptake or transport disruption of trophic factorsby motor neurons (reviewed in Holzbaur (2004) Trends Cell Biol.14:233-40). Thus, ALS might be treated by therapies that rejuvenate adegenerating neuron by providing an optimal survival environment. Anerve's environment includes nonneuronal cells such as glia and themuscle cells innervated by the motor neuron. This environment providestrophic and growth factors that are endocytosed by the neuron andtransported via retrograde axonal transport to the cell body (Chao(2003) Neuron 39:1-2; Holzbaur, supra).

FALS has been modeled in both mouse and rat by the overexpression ofmutant SOD1 (Howland et al. (2002) Proc. Natl. Acad. Sci. U.S.A.99:1604-09). Transgenic mice overexpressing the G93A form of mutant SOD1display muscle weakness and atrophy by 90 to 100 days of age, andtypically die near 130 days of age (Gurney et al. (1994) Science264:1772-75). However, the underlying SODG93 A-induced pathology, whichincludes grip strength weakness and loss of neuromuscular junctions, issignificant as early as 50 days of age (Frey et al. (2000) J. Neurosci.20:2534-42; Fisher et al. (2004) Exp. Neuro. 185:232-40; Ligon et al.(2005) NeuroReport 16:533-36; Wooley et al. (2005) Muscle Nerve32:43-50). Transgenic rats expressing the SODG93A mutation follow asimilar time course of degeneration (Howland et al., supra). Recent workhas suggested that the development of pathology is not cell autonomous,consistent with the hypothesis that the degeneration of motor neuronsobserved in ALS occurs via multiple mechanisms, including the disruptionof uptake and transport of trophic factors by the motor neuron (seeabove). Clement and coworkers have used chimeric mice to show that wildtype nonneuronal cells can extend survival of motor neurons expressingmutant SOD1 (Clement et al. (2003) Science 302:113-17). Theseobservations have led to the investigation of therapies that might slowneuronal degeneration by providing an optimal microenvironment forsurvival. For example, treatment of the SODG93A mouse via directintramuscular injection of virally expressed growth factors (includingIGF-1, GDNF and VEGF) prolongs animal survival (Kaspar et al. (2003)Science 301:839-42; Azzouz et al. (2004) Nature 429:413-17; Wang et al.(2002) J. Neurosci. 22:6920-28). In addition, muscle-specific expressionof a local IGF-1-specific isoform (mIGF-1) stabilizes neuromuscularjunctions, enhances motor neuron survival and delays onset andprogression of disease in the SODG93A transgenic mouse model, indicatingthat direct effects on muscle can impact disease onset and progressionin transgenic SOD1 animals (Dobrowolny et al. (2005) J. Cell Biol.168:193-99). Links between muscle hypermetabolism and motor neuronvulnerability have also been reported in ALS mice, supporting thehypothesis that defects in muscle may contribute to the disease etiology(Dupois et al. (2004) Proc. Natl. Acad. Sci. U.S.A. 101:11159-64). Thus,enhancing muscle growth should provide improved local support for motorneurons, and therefore result in therapeutic benefits.

Inhibition of myostatin expression leads to both muscle hypertrophy andhyperplasia (Lee and McPherron, supra; McPherron et al., supra).Myostatin negatively regulates muscle regeneration after injury, andlack of myostatin in GDF-8 null mice results in accelerated muscleregeneration (McCroskery et al., (2005) J. Cell. Sci. 118:3531-41).Myostatin-neutralizing antibodies increase body weight, skeletal musclemass, and muscle size and strength in the skeletal muscle of wild typemice (Whittemore et al. (2003) Biochem. Biophys. Res. Commun.300:965-71) and the mdx mouse, a model for muscular dystrophy(Bogdanovich et al. (2002) Nature 420:418-21; Wagner et al. (2002) Ann.Neurol. 52:832-36). Furthermore, myostatin antibody in these micedecreased the damage to the diaphragm, a muscle that is also targetedduring ALS pathogenesis. It has been hypothesized that the action ofgrowth factors, such as HGF, on muscle may be due to inhibition ofmyostatin expression (McCroskery et al. (2005), supra), thereby helpingto shift the “push and pull,” or balance, between regeneration anddegeneration in a positive direction. Thus, GDF-8 inhibition presents asa potential pharmacological target for the treatment of ALS, musculardystrophy (MD), and other GDF-8-associated disorders, e.g.,neuromuscular disorders for which it is desirable to increase musclemass, strength, size, etc. With the availability of animal models (mouseand rat) of ALS, it is possible to test therapeutics in two differentspecies, thus increasing the confidence of therapeutic effects in humansin vivo.

In addition to neuromuscular disorders in humans, there are also growthfactor-related conditions associated with a loss of bone, such asosteoporosis and osteoarthritis, which predominantly affect the elderlyand/or postmenopausal women. In addition, metabolic bone diseases anddisorders include low bone mass due to chronic glucocorticoid therapy,premature gonadal failure, androgen suppression, vitamin D deficiency,secondary hyperparathyroidism, nutritional deficiencies, and anorexianervosa. Although many current therapies for these conditions functionby inhibiting bone resorption, a therapy that promotes bone formationwould be a useful alternative treatment. Because GDF-8 plays a role inbone development as well as muscular development, regulation of GDF-8 isalso an excellent pharmacological target for the treatment ofbone-degenerative disorders.

Thus, a need exists to develop compounds and methods of treatment thatcontribute to an overall increase in muscle mass and/or strength and/orbone density, etc., particularly in humans, and particularly in thosesuffering from ALS and other muscle-wasting diseases as well asbone-degenerative disorders. Generating neutralizing antibodies andother small molecules with enhanced affinity to GDF-8 is an excellentpharmacological approach to treat these disorders.

SUMMARY OF THE INVENTION

The GDF-8 antagonists of the invention relate to antibodies (e.g.,intact antibodies and antigen-binding fragments thereof), which arereferred to herein as “anti-GDF-8 antibodies” or “GDF-8 antibodies.” Inone embodiment, an anti-GDF-8 antibody reduces, neutralizes, and/orantagonizes at least one GDF-8-associated activity (i.e., “GDF-8activity”). The present invention thus provides methods to treat variousbone, muscle, glucose and adipose disorders associated with GDF-8activity using these anti-GDF-8 antibodies. The present inventiondiscloses that GDF-8 antagonists, e.g., GDF-8 antibodies, are highlyeffective therapeutics when used to treat animals suffering from ALS,and that administration of such antibodies reduces the wasting ofmuscles targeted during ALS pathology, e.g., diaphragm, gastrocnemius,etc. In addition, the present invention discloses that these antagonistsare highly effective at increasing muscle mass and grip strength inALS-afflicted animals. As a result, the invention teaches thatanti-GDF-8 antibodies are effective compositions to treatGDF-8-associated disorders, e.g., ALS, muscle wasting disorders or otherdisorders that result from GDF-8 dysregulation.

In one aspect, the invention features a method of treating (e.g.,curing, suppressing), ameliorating, or preventing (e.g., delaying orpreventing the onset, recurrence or relapse of) a GDF-8-associateddisorder in a subject. The method includes: administering to the subjecta GDF-8 antagonist, e.g., an anti-GDF-8 antibody, in an amountsufficient to treat or prevent the GDF-8-associated disorder. The GDF-8antagonist, e.g., the anti-GDF-8 antibody, can be administered to thesubject alone or in combination with other therapeutic modalities asdescribed herein. The GDF-8 antibody can be administeredtherapeutically, prophylactically, or both. In one embodiment, thesubject is a mammal, e.g., a human suffering from a GDF-8-associateddisorder, including, e.g., bone and muscle disorders. Preferably, thesubject is a human. More preferably, the subject is a human sufferingfrom a GDF-8-associated disorder as described herein.

In one embodiment, the present invention provides safe and effectivetherapeutic methods for diagnosing, prognosing, monitoring, screening,treating, ameliorating, and/or preventing GDF-8-associated disorders,e.g., muscle disorders, neuromuscular disorders, bone-degenerativedisorders, metabolic or induced bone disorders, adipose disorders,glucose metabolism disorders, or insulin-related disorders whichinclude, but are not limited to, glucose homeostasis, type 2 diabetes,impaired glucose tolerance, metabolic syndrome (i.e., a syndromeinvolving the simultaneous occurrence of a group of health conditions,which may include insulin resistance, abdominal obesity, dyslipidemia,hypertension, chronic inflammation, a prothrombotic state, etc., thatplaces a person at high risk for type 2 diabetes and/or heart disease),insulin resistance (e.g., resistance induced by trauma such as burns ornitrogen imbalance), adipose tissue disorders (e.g., obesity,dyslipidemia, nonalcoholic fatty liver disease, etc.), HIV-inducedmuscle wasting, muscular dystrophy (including Duchenne's musculardystrophy), amyotrophic lateral sclerosis (“ALS”), muscle atrophy, organatrophy, frailty, congestive obstructive pulmonary disease, sarcopenia,cachexia, muscle wasting syndromes, osteoporosis, osteoarthritis,metabolic bone diseases, and metabolic bone disorders (including lowbone mass due to chronic glucocorticoid therapy, premature gonadalfailure, androgen suppression, vitamin D deficiency, secondaryhyperparathyroidism, nutritional deficiencies, and anorexia nervosa). Ina preferred, but not limiting, embodiment, the invention provides safeand effective therapeutic methods for diagnosing, prognosing,monitoring, screening, treating, ameliorating, and/or preventing aGDF-8-associated disorder, e.g., a muscular disorder in vertebrates,particularly mammals, and more particularly humans. In a most preferredembodiment of the invention, the GDF-8-associated disorder, e.g., muscledisorder, diagnosed, prognosed, monitored, screened, treated,ameliorated, and/or prevented is ALS.

In another embodiment, this invention provides methods of inhibitingGDF-8 function in vivo or in vitro. These methods are useful fortreating GDF-8-associated disorders, e.g., muscle and bone degenerativedisorders, particularly muscle disorders such as ALS, and for increasingmuscle mass and/or bone strength and/or density. The methods are alsouseful for increasing muscle mass and bone density in normal animalsincluding, but not limited to, humans. The subject methods can be usedin vitro (e.g., in a cell-free system, in culture, etc.), ex vivo, or invivo. For example, GDF-8 receptor-expressing cells can be cultured invitro in culture medium and contacted with, e.g., one or more anti-GDF-8antibodies, e.g., as described herein. Alternatively, the method can beperformed on cells present within a subject, e.g., as part of an in vivo(e.g., therapeutic or prophylactic) protocol.

Accordingly, in one aspect, the invention features a GDF-8 antagonist,e.g., an isolated antibody, that interacts with, e.g., binds to, andneutralizes and/or inhibits, GDF-8. In particular, the GDF-8 proteinbound by the GDF-8 antibody is mammalian, e.g., human, sheep, nonhumanprimate GDF-8. In another embodiment, the invention provides antibodiesthat bind GDF-8 with high affinity, e.g., with a Kd of at least 10⁻⁷ M,preferably 10⁻⁸, 10⁻⁹, 10⁻¹⁰, more preferably, 10⁻¹¹ M or higher. Theaffinity and binding kinetics of the anti-GDF-8 antibody can be testedusing several well-known methods, e.g., biosensor technology (Biacore,Piscataway, N.J.).

In one embodiment, the anti-GDF-8 antibody (e.g., an intact antibody oran antibody fragment (e.g., a Fab, F(ab′)₂, Fv or a single chain Fvfragment)) is a monoclonal antibody. The antibody may be a human,humanized, chimeric, or an in vitro-generated antibody. In a preferred,but not limiting, embodiment, an anti-GDF-8 antibody of the invention isa humanized antibody.

These anti-GDF-8 antibodies can be used to diagnose, prognose, monitor,screen, treat, ameliorate, and/or prevent muscle, bone, adipose andglucose metabolism-related disorders. A nonlimiting example of ananti-GDF-8 antibody is referred to herein as “RK35,” and includes bothmouse and modified antibodies, e.g., chimeric or humanized forms. Thenucleotide and amino acid sequences for the heavy chain variable regionof mouse RK35 are set forth herein as SEQ ID NO:2 and SEQ ID NO:3,respectively. The nucleotide and amino acid sequences for the heavychain variable region of humanized RK35 are set forth herein as SEQ IDNO:6 and SEQ ID NO:7, respectively. The nucleotide and amino acidsequences for the light chain variable region of mouse RK35 are setforth herein as SEQ ID NO:4 and SEQ ID NO:5, respectively. Thenucleotide and amino acid sequences for the light chain variable regionof humanized RK35 are set forth herein as SEQ ID NO:8 and SEQ ID NO:9,respectively.

In a preferred, but not limiting, embodiment of the invention, theantibody is a mouse or humanized antibody to GDF-8. In a more preferredembodiment of the invention, the antibody is comprised of the VH(variable heavy) domain set forth in SEQ ID NO:3 and the VL (variablelight) domain set forth in SEQ ID NO:5. In another preferred embodimentof the invention, the antibody is comprised of the VH domain set forthin SEQ ID NO:7 and the VL domain set forth in SEQ ID NO:9. Additionalembodiments of the invention comprise one or more VH or VL domainslisted in Table 1.

Other embodiments of the invention comprise an H3 fragment of RK35,i.e., the sequence set forth as SEQ ID NO:12. In yet another embodiment,a GDF-8 antagonist comprises one, two, or three complementaritydetermining regions (CDRs) from a heavy chain variable region of anantibody disclosed herein with sequences selected from SEQ ID NOs:10-12and 20-22. In yet another embodiment, an antagonist of the inventioncomprises one, two, or three CDRs from a light chain variable region ofan antibody disclosed herein with sequences selected from SEQ IDNOs:13-15 and 23-25. In yet another embodiment, the antibody comprisesone, two, three, four, five, or six CDRs with sequences selected fromSEQ ID NOs:10-15 and 20-25.

The heavy and light chains of an anti-GDF-8 antibody of the inventionmay be full-length (e.g., an antibody can include at least one, andpreferably two, complete heavy chains, and at least one, and preferablytwo, complete light chains) or may include an antigen-binding fragment(e.g., a Fab, F(ab′)₂, Fv or a single chain Fv fragment (“scFv”)). Inother embodiments, the antibody heavy chain constant region is chosenfrom, e.g., IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE,particularly chosen from, e.g., IgG1, IgG2, IgG3, and IgG4, moreparticularly, IgG1 (e.g., human IgG1). In another embodiment, theantibody light chain constant region is chosen from, e.g., kappa orlambda, particularly kappa (e.g., human kappa). In one embodiment, theconstant region is altered, e.g., mutated, to modify the properties ofthe antibody (e.g., to increase or decrease one or more of: Fc receptorbinding, antibody glycosylation, the number of cysteine residues,effector cell function, or complement function). For example, the humanIgG1 constant region can be mutated at one or more residues, e.g., oneor more of residues 117 and 120 of SEQ ID NO:19. In one embodiment, theanti-GDF-8 antibody comprises the human IgG1 constant region shown inSEQ ID NO:19. In another embodiment, the anti-GDF-8 antibody comprises ahuman kappa sequence, e.g., the sequence shown as SEQ ID NO:17.

In another embodiment, the invention provides GDF-8 antibodies as novelantibody fragments that bind GDF-8 and retain the ability to neutralizeor reduce GDF-8 activity. In a preferred, but not limiting, embodimentof the invention, the antibody fragment is selected from the groupconsisting of a dAb fragment, a diabody, an Fd fragment, an Fabfragment, an F(ab′)₂ fragment, an scFV fragment, and an Fv fragment. Ina more preferred embodiment of the invention, the antibody fragment isencoded by a polynucleotide selected from SEQ ID NOs:2, 4, 6 or 8. Inanother preferred embodiment of the invention, the antibody fragmentcomprises an amino acid sequence selected from an amino acid sequenceset forth in SEQ ID NOs:10-15 and 20-25. In another preferredembodiment, the invention provides novel antibody fragments that differin sequence (e.g., due to the redundancy of the genetic code) from thosesequences listed in Table 1, yet retain the ability to bind GDF-8 andneutralize or reduce GDF-8 activity.

In another embodiment, the anti-GDF-8 antibody comprises at least one,two, three or four antigen-binding regions, e.g., variable regions,having an amino acid sequence as listed in Table 1 (SEQ ID NOs:3 or 7for VH, and/or SEQ ID NOs:5 or 9 for VL), or a sequence substantiallyidentical thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% ormore identical thereto, or which differs by no more than 1, 2, 5, 10 or15 amino acid residues from SEQ ID NOs:3, 5, 7 or 9). In anotherembodiment, the antibody includes a VH and/or VL domain encoded by anucleic acid having a nucleotide sequence as listed in Table 1 (SEQ IDNOs:2 or 6 for VH, and/or SEQ ID NOs:4 or 8 for VL), or a sequencesubstantially identical thereto (e.g., a sequence at least about 85%,90%, 95%, 99% or more identical thereto, or which differs by no morethan 3, 6, 15, 30 or 45 nucleotides from SEQ ID NOs:2, 4, 6, or 8). Inyet another embodiment, the antibody comprises one, two, or three CDRsfrom a heavy chain variable region having amino acid sequences as listedin Table 1 (SEQ ID NOs:10-12 and 20-22), or a sequence substantiallyhomologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99%or more identical thereto, and/or having one or more substitutions,e.g., conserved substitutions). In yet another embodiment, the antibodycomprises at least one, two, or three CDRs from a light chain variableregion having amino acid sequences as listed in Table 1 (SEQ IDNOs:13-15 and 23-25), or a sequence substantially homologous thereto(e.g., a sequence at least about 85%, 90%, 95%, 99% or more identicalthereto, and/or having one or more substitutions, e.g., conservedsubstitutions). In yet another embodiment, the antibody comprises one,two, three, four, five or six CDRs from heavy and light chain variableregions having amino acid sequences as listed in Table 1 (SEQ IDNOs:10-12 and 20-22 for VH CDRs; and SEQ ID NOs:13-15 and 23-25 for VLCDRs), or a sequence substantially homologous thereto (e.g., a sequenceat least about 85%, 90%, 95%, 99% or more identical thereto, and/orhaving one or more substitutions, e.g., conserved substitutions).

In another embodiment, the anti-GDF-8 antibody comprises a human IgG1constant region having an amino acid sequence as set forth in SEQ IDNO:19 or a sequence substantially homologous thereto (e.g., a sequenceat least about 85%, 90%, 95%, 99% or more identical thereto, or whichdiffers by no more than 1, 2, 5, 10, 50, or 100 amino acid residues fromSEQ ID NO:19). In another embodiment, the anti-GDF-8 antibody comprisesa human kappa constant chain, e.g., a human kappa constant chain havingan amino acid sequence as set forth in SEQ ID NO:17 or a sequencesubstantially homologous thereto (e.g., a sequence at least about 85%,90%, 95%, 99% or more identical thereto, or which differs by no morethan 1, 2, 5, 10, 20, or 50 amino acid residues from SEQ ID NO:17). Inyet another embodiment, the antibody comprises a human IgG1 constantregion and a human kappa constant chain as described herein.

In a preferred, but not limiting, embodiment, the invention providesantibodies encoded by polynucleotides set forth in SEQ ID NOs:2, 4, 6,or 8. In another preferred embodiment, the invention provides antibodiesencoded by polynucleotide sequences that hybridize under stringentconditions to the polynucleotides set forth in SEQ ID NOs:2, 4, 6, or 8.In another preferred embodiment, the invention provides antibodiesencoded by polynucleotides, which differ from those sequences set forthin SEQ ID NOs:2, 4, 6, or 8, but due to the degeneracy of the geneticcode, encode an amino acid sequence set forth in SEQ ID NOs:3, 5, 7, 9,or 10-15.

The GDF-8 antagonist, e.g., an anti-GDF-8 antibody, can be derivatizedor linked to another functional molecule, e.g., another peptide orprotein (e.g., an Fab fragment). For example, a fusion protein or anantibody, or antigen-binding portion, can be functionally linked (e.g.,by chemical coupling, genetic fusion, noncovalent association orotherwise) to one or more other molecular entities, such as an antibody(e.g., a bispecific or a multispecific antibody), toxins, radioisotopes,cytotoxic or cytostatic agents, among others.

A further aspect of the invention provides as GDF-8 antagonists purifiedand isolated nucleic acids that encode the GDF-8 antagonists, e.g.,anti-GDF-8 antibodies, of the invention. In one embodiment, theinvention provides polynucleotides comprised of a sequence encoding a VH(SEQ ID NO:3 or SEQ ID NO:7), VL (SEQ ID NO:5 or SEQ ID NO:9), and/orCDR (SEQ ID NOs:10-15 and 20-25) as listed in Table 1. In anotherembodiment, the invention provides polynucleotides that hybridize understringent conditions to nucleic acids encoding a VH, VL, or CDR (SEQ IDNOs:3, 5, 7, 9, 10-15, or 20-25) as listed in Table 1. In anotherembodiment, the invention provides nucleic acids that comprise SEQ IDNOs:2, 4, 6, or 8 or fragments of SEQ ID NOs:2, 4, 6, or 8. In yet afurther embodiment, the invention provides polynucleotides thathybridize under stringent conditions to SEQ ID NOs:2, 4, 6 or 8. Anotheraspect of the invention provides host cells and vectors comprising thepolynucleotides of the invention as GDF-8 antagonists.

The antibodies of the invention possess a number of useful properties.First, the antibodies are capable of binding mature GDF-8 with highaffinity. Second, the disclosed antibodies inhibit GDF-8 activity invitro and in vivo. Third, the disclosed antibodies inhibit GDF-8activity associated with negative regulation of skeletal muscle mass andbone density. Fourth, the disclosed antibodies are an effectivetreatment for muscular disorders, particularly ALS. These antibodieshave many additional uses, including diagnosing, prognosing, monitoring,screening, treating, ameliorating, and/or preventing GDF-8-associateddisorders, e.g., muscle and/or bone-associated disorders.

Other aspects of the invention provide compositions comprised of a GDF-8antagonist of the invention, e.g., an anti-GDF-8 antibody of theinvention, and the use of such compositions in inhibiting orneutralizing GDF-8 in animals, particularly in humans or other animalswith muscular disorders such as ALS. The antibodies of the invention mayalso be used in a GDF-8-associated disorder, e.g., in a disorder inwhich it is desirable to increase muscle tissue or bone density. Forexample, anti-GDF-8 antibodies may be used in therapies and compositionsto repair damaged muscle, e.g., myocardium, diaphragm, etc. ExemplaryGDF-8-associated disorders and diseases treated by the disclosed methodsand compositions include muscle and neuromuscular disorders such asmuscular dystrophy (including Duchenne's muscular dystrophy);amyotrophic lateral sclerosis; muscle atrophy; organ atrophy; frailty;tunnel syndrome; congestive obstructive pulmonary disease (COPD);sarcopenia, cachexia, and other muscle wasting syndromes; adipose tissuedisorders (e.g., obesity); type 2 diabetes; impaired glucose tolerance;metabolic syndromes (e.g., syndrome X); insulin resistance (includingresistance induced by trauma, e.g., burns or nitrogen imbalance), andbone-degenerative diseases (e.g., osteoarthritis and osteoporosis). In apreferred, but not limiting, embodiment of the invention, a compositioncontaining an anti-GDF-8 antibody is used in a method of treating,reducing, or ameliorating ALS.

In another aspect, the invention provides compositions, e.g.,pharmaceutical compositions, that include a pharmaceutically acceptablecarrier and at least one GDF-8 antagonist, e.g., an anti-GDF-8 antibodydescribed herein. In one embodiment, the compositions, e.g.,pharmaceutical compositions, comprise a combination of two or more ofthe aforesaid GDF-8 antagonists, e.g., anti-GDF-8 antibodies orfragments thereof. Also within the scope of the invention arecombinations of the GDF-8 antagonist, e.g., an anti-GDF-8 antibody, witha therapeutic agent, e.g., growth factor inhibitors, immunosuppressants,anti-inflammatory agents (e.g., systemic anti-inflammatory agents),metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or cytostaticagents.

In yet another embodiment, the GDF-8 antagonist, e.g., an anti-GDF-8antibody, or a pharmaceutical composition thereof, is administered aloneor in combination therapy, i.e., combined with other agents, e.g.,therapeutic agents, which are useful for treating GDF-8-associateddisorders.

In addition to use in the treatment of various diseases or disorders,anti-GDF-8 antibodies may be used as diagnostic tools to quantitativelyor qualitatively detect GDF-8 protein or protein fragments in abiological sample. The presence or amount of GDF-8 protein detected canbe correlated with one or more of the medical conditions listed herein.Thus, in one embodiment, the invention provides methods to diagnose,prognose, monitor, and/or screen for GDF-8-associated disorders.

In another aspect, the invention provides a method for detecting thepresence of GDF-8 in a sample in vitro (e.g., a biological sample, suchas serum, plasma, tissue, biopsy). The subject method can be used todiagnose a GDF-8-associated disorder, e.g., a bone, muscle, adipose orglucose metabolism-associated disorder. The method includes: (i)contacting the sample or a control sample with an anti-GDF-8 antibody asdescribed herein; and (ii) detecting formation of a complex between theanti-GDF-8 antibody, and the sample or the control sample, wherein asubstantially significant change in the formation of the complex in thesample relative to the control sample is indicative of the presence ofGDF-8 in the sample.

In yet another aspect, the invention provides a method for detecting thepresence of GDF-8 in vivo in a subject (e.g., in vivo imaging in asubject). The subject method can be used to diagnose a GDF-8-associateddisorder, e.g., ALS. The method includes: (i) administering ananti-GDF-8 antibody as described herein to a subject or a controlsubject under conditions that allow binding of the antibody to GDF-8;and (ii) detecting formation of a complex between the antibody andGDF-8, wherein a substantially significant difference in the formationof the complex in the subject relative to the control subject providesan indication related to the presence of GDF-8.

Other embodiments of the invention provide a method of diagnosing ordetecting whether a patient is suffering from a GDF-8-associateddisorder (e.g., muscle disorder, neuromuscular disorder, bonedegenerative disorder, metabolic or induced bone disorder, adiposedisorder, glucose metabolism disorder, or insulin-related disorder)comprising the steps of: (a) obtaining a sample from a patient ofinterest; (b) contacting the sample with an anti-GDF-8 antibody asdescribed herein; (c) determining the level of GDF-8 present in thepatient sample; and (d) comparing the level of GDF-8 in the patientsample to the level of GDF-8 in a control sample, wherein a substantialincrease, decrease, or similarity in the level of GDF-8 in the patientsample compared to the level of GDF-8 in the control sample indicateswhether the patient is suffering from a GDF-8-associated disorder.

Another further embodiment of a method for diagnosing or detectingwhether a patient is suffering from a GDF-8-associated disorderdescribed herein comprises the steps of: (a) obtaining a first sampletaken from the patient of interest; (b) contacting the first sample withan anti-GDF-8 antibody as described herein; (c) determining the level ofa GDF-8 in the first sample; (d) obtaining a second sample from anindividual not afflicted with the GDF-8-associated disorder; (e)contacting the second sample with an anti-GDF-8 antibody as describedherein; (f) determining the level of GDF-8 in the second sample; and (g)comparing the levels of GDF-8 in the first and second samples, wherein asubstantial increase, decrease, or similarity in the level of firstsample compared to the second sample indicates whether the patient issuffering from a GDF-8-associated disorder caused (in part or in full)by overexpression of GDF-8. For example, an increase in the level ofGDF-8 in the first sample compared to the second sample may indicatethat the patient is suffering from the GDF-8-associated disorder. Incontrast, a decrease or similarity in the level of GDF-8 in the firstsample compared to the second sample may indicate that the patient isnot suffering from the GDF-8-associated disorder.

Antibodies of the invention are also useful in methods of prognosing thelikelihood that a patient will develop a GDF-8-associated disorder,e.g., a muscle disorder, neuromuscular disorder, bone degenerativedisorder, metabolic or induced bone disorder, adipose disorder, glucosemetabolism disorder, or insulin-related disorder. In a preferred, butnonlimiting, embodiment, the method comprises the steps of: (a)obtaining a first sample from a patient of interest; (b) contacting thefirst sample with an anti-GDF-8 antibody as described herein; (c)determining the level of GDF-8 in the first sample; (d) obtaining asecond sample from an individual not afflicted with the GDF-8-associateddisorder; (e) contacting the second sample with an anti-GDF-8 antibodyas described herein; (f) determining the level of GDF-8 in the secondsample; and (g) comparing the levels of GDF-8 in the first and secondsamples, wherein an increase, decrease, or similarity in the level ofGDF-8 in the first sample as compared with the second sample indicatesthe likelihood that the patient will develop the GDF-8-associateddisorder. For example, for a GDF-8-associated disorder caused (in partor in full) by overexpression of GDF-8, it is likely that the patientwill develop the GDF-8-associated disorder if the first sample has anincreased level of GDF-8 compared to second sample. In contrast, for aGDF-8-associated disorder caused (in part or in full) by overexpressionof GDF-8, it is unlikely that the patient will develop theGDF-8-associated disorder if the first sample has a similar or decreasedlevel of GDF-8 compared to second sample.

Antibodies of the invention are also useful in methods of monitoring theseverity of a GDF-8-associated disorder, e.g., muscle disorder,neuromuscular disorder, bone degenerative disorder, metabolic or inducedbone disorder, adipose disorder, glucose metabolism disorder, orinsulin-related disorder. In a preferred, but not limiting, embodiment,the method comprises the steps of: (a) obtaining a first sample takenfrom a patient of interest at a first time point; (b) contacting thefirst sample with an anti-GDF-8 antibody as described herein; (c)determining the level of GDF-8 in the first sample; (d) obtaining asecond sample taken from the patient at a second time point; (e)contacting the second sample with an anti-GDF-8 antibody as describedherein; (f) determining the level of GDF-8 in the second sample; and (g)comparing the levels of GDF-8 in the first and second samples, whereinan increase, decrease, or similarity in the level of GDF-8 in the secondsample indicates whether the GDF-8-associated disorder has changed inseverity. In one embodiment, a method of monitoring of the invention isused to monitor ALS, and a decrease in the level of GDF-8 in the secondsample indicates that ALS has decreased in severity.

An additional method of monitoring a disorder as described hereincomprises the steps of: (a) obtaining a first sample from a patient ofinterest; (b) contacting the first sample with an anti-GDF-8 antibody asdescribed herein; (c) determining the level of GDF-8 in the firstsample; (d) obtaining a second sample from an individual not afflictedwith a muscle disorder, neuromuscular disorder, bone degenerativedisorder, metabolic or induced bone disorder, adipose disorder, glucosemetabolism disorder, or insulin-related disorder; (e) contacting thesecond sample with an anti-GDF-8 antibody as described herein; (f)determining the level of GDF-8 in the second sample; and (g) comparingthe levels of GDF-8 in the first and second samples, wherein anincrease, decrease, or similarity in the level of GDF-8 in the firstsample compared to the second sample indicates the severity of the GDF-8disorder at that point. In one embodiment, a method of monitoring of theinvention is used to monitor ALS, and a decrease or similarity in thelevel of GDF-8 in the first sample compared to the second sampleindicates that ALS has low severity.

Preferably, the antibody is directly or indirectly labeled with adetectable substance to facilitate detection of the bound or unboundantibody. Suitable detectable substances include various enzymes,prosthetic groups, fluorescent materials, luminescent materials andradioactive materials.

Methods for delivering or targeting an antagonist of the invention,e.g., an antibody, to a GDF-8-expressing cell in vivo are also disclosedherein and are within the scope of the invention.

Kits comprising the GDF-8 antagonists, e.g., the anti-GDF-8 antibodies,of the invention for therapeutic and diagnostic uses are also within thescope of the invention.

Additional objects of the invention will be set forth in the followingdescription. Various objects, aspects, and advantages of the inventionwill be realized and attained by means of the elements and combinationsparticularly pointed out in the claims.

It is to be understood that both the foregoing general description andthe following detailed description are exemplary and explanatory only,and are not restrictive of the invention as claimed.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-C. Characterization of the RK35 anti-GDF-8 antibody. FIG. 1A.Direct binding of RK35 antibody to GDF-8, as measured in an ELISA assaywith biotinylated GDF-8. The binding affinity of RK35 antibody (circles)for GDF-8 was determined to be 4 nM. Control IgG shows no appreciablebinding (squares). FIG. 1B. Effect of RK35 antibody on GDF-8 binding toits high affinity receptor. In a competition ELISA using the highaffinity GDF-8 receptor, ActRIIB was used to measure the GDF-8inhibitory activity of RK35. The binding of biotinylated GDF-8 toimmobilized human chimeric protein ActRIIB fused to the human IgGconstant region (Fc) was evaluated in the absence (diamonds) or presenceof various concentrations of RK35 mAb, soluble ActRIIB or control IgG.Soluble ActRIIB-Fc receptor (squares) and irrelevant mouse IgG(triangles) were used as positive and negative controls, respectively.RK35 (circles) blocked the binding of biotinylated GDF-8 to immobilizedActRIIB with an IC₅₀˜2.5 nM. FIG. 1C. Inhibition of GDF-8-induced signaltransduction. Rhabdomyosarcoma cells expressing a TGF-βpromoter-luciferase fusion gene were treated with 10 ng/ml of GDF-8 inthe absence (squares) or presence (circles) of varying concentrations ofRK35 antibody. RK35 reduced the GDF-8 induction of luciferase activityin a dose-responsive manner, with an IC₅₀ of 0.2 nM. Background(diamonds) signal was measured with no GDF-8 added.

FIG. 2A-F. Inhibition of myostatin leads to increased body weight andincreased muscle mass in both SODG93 A mice and rats. FIG. 2A. Bodyweights of RK35-treated (squares) (n=11) and PBS-treated (diamonds)(n=11) transgenic SODG93A mice and PBS-treated littermate control (wildtype) mice (triangles) (n=9). FIG. 2B. Body weights of male (circles)and female (triangles) RK35-treated and male (squares) and female(diamonds) PBS-treated transgenic SODG93A rats (n=10 per group). FIG.2C. Muscle mass of RK35- and PBS-treated SODG93A and PBS-treatedlittermate control mice (n=9-12) during early-stage disease. Wet weightswere determined for the gastrocnemius (gastroc), cranial tibialis(tibialis), quadriceps (quad) and diaphragm (diaphragm) muscles from88-day old wild type mice treated with PBS (black bars), SODG93A micetreated with PBS (white bars), and SODG93A mice treated with RK35 (greybars). FIG. 2D. Muscle mass from SODG93A rats, treated with PBS (whitebars) or RK35 (grey bars), at early-stage disease (˜95 days) (n=7 pergroup). FIG. 2E. Muscle mass of wild type mice treated with PBS (blackbars), SODG93A mice treated with PBS (white bars), and SODG93A micetreated with RK35 (grey bars) at end-stage disease (˜134 days). FIG. 2F.Muscle mass from SODG93A rats, treated with PBS (white bars) or RK35(grey bars) at end-stage disease (˜128 days). Asterisks (*) denotestatistically (p<0.05) differences between indicated groups.

FIG. 3A-3C. Myostatin inhibition enhances muscle strength in SODG93Amice and rats. FIG. 3A. Hindlimb grip strength in PBS-treated wild typemice (triangles), and SODG93A mice treated with either PBS (diamonds) orRK35 (squares) as a function of age. Hind limb grip strength isexpressed as compression in kilograms (kg). FIG. 3B. Forelimb gripstrength in PBS-treated wild type mice (triangles), and SODG93A micetreated with either PBS (diamonds) or RK35 (squares) as a function ofage. FIG. 3C. Forelimb grip strength in wild type rats treated with PBS(WT+PBS), or SODG93A rats treated with PBS (SOD+PBS) or RK35 (SOD+RK35).For rats, measurements were taken during a 4-week interval correspondingto early disease phase, between 95-110 days in age. Forelimb gripstrength is expressed as tension in kilograms (kg). Asterisks (*) denotea statistically significant difference (p<0.0001) between indicatedgroups.

FIG. 4A-K. Effects of myostatin inhibition on muscle structure andfunction in SODG93A rodents. Hematoxylin and eosin staining of medialgastrocnemius muscle from mice at 88 days indicates significant atrophyin (FIG. 4B) PBS-treated SODG93A mice, in comparison to either (FIG. 4A)wild type or (FIG. 4C) RK35-treated SODG93A mice. Hematoxylin and eosinstaining of medial gastrocnemius muscle from both (FIG. 4E) PBS-treatedand (FIG. 4F) RK35-treated SODG93A mice at end-stage indicates bothsignificant muscle atrophy and centrally placed nuclei (arrowheads)compared to (FIG. 4D) wild type mouse gastrocnemius. Hematoxylin andeosin staining of diaphragm from (FIG. 4G) PBS-treated wild type miceand (FIG. 4H) PBS- or (FIG. 4I) RK35-treated SODG93A mice, respectively,at end-stage. Examples of atrophic myofibers are marked (“a”). Theasterisk in panel H denotes fiber splitting. Bars shown denote 50 μm inscale in panels A-F and 25 μm in panels G-I. Panel FIG. 4J: EMGinterference pattern showing inspiratory bursts, recorded from thediaphragm muscles of wild type rats treated with PBS (WT+PBS) or SODG93Arats treated with PBS (SOD+PBS) or RK35 (SOD+RK35). Panel FIG. 4K: EMGburst spike rates (in Hz) from the diaphragm muscles of wild type rats(n=4), and from SODG93A rats treated either with vehicle (PBS, n=9) orRK35 (n=8). Asterisks (*) denote a statistically significant difference(p<0.05) between the indicated groups.

FIG. 5A-D. RK35 treatment slows the decrease in muscle fiber diameter ingastrocnemius muscle through early-stage disease in SODG93A mice, and indiaphragm through end-stage disease. Fiber diameters were measured bymorphometry on gastrocnemius muscle from PBS-treated (FIG. 5A) andRK35-treated (FIG. 5B) SODG93A mice and PBS-treated wild type mice (FIG.5C) at 88 days. Means were significantly different by ANOVA (p<0.0001);pairwise comparisons by Tukey's multiple comparison post-test were alsosignificant (p<0.001). By end-stage, no significant differences in fiberdistribution were observed in the gastrocnemius muscle of PBS-treatedand RK35-treated SODG93A mice (data not shown). FIG. 5D. Analysis offiber diameters of diaphragm muscle from end-stage PBS-treated andRK35-treated SODG93A mice in comparison to age-matched wild type controlmice. Diaphragm muscle from RK35-treated SODG93A mice shows a fiberdiameter distribution intermediate between PBS-treated SODG93A mice andwild type control mice at end-stage. Means were significantly differentby ANOVA (p<0.0001); pairwise comparisons by Tukey's multiple comparisonpost-test were also significant (p<0.01). Three muscles per group wereanalyzed; linear measurements of the maximum diameter of the minor axisof at least two hundred fibers were taken, using Zeiss Axiovisionsoftware. Fiber diameters were binned in 20 μm intervals, and frequencyhistograms were generated for each muscle group.

FIG. 6A-J. Effect of anti-myostatin treatment on motor neuron loss inthe ventral horn of the spinal cord. Shown are stereological analyses oflarge motor neurons (area greater than 300 (μm²) from the L3-5 regionsof the ventral horn from SODG93A mice treated with either PBS (SOD+PBS)or RK35 (SOD+RK35) at early-stage (FIG. 6A) and end-stage (FIG. 6C)disease in comparison to age-matched wild type mice (WT+PBS). RK35treatment showed a trend towards reversing the motor neuron loss(p=0.08) in early-stage disease (FIG. 6A). Individual counts of largehealthy motor neurons with visible nucleoli were performed onNISSL-stained sections L3-5 from SODG93A mice treated with either PBS orRK35 at (FIG. 6B) early-stage and (FIG. 6D) end-stage disease incomparison to age-matched wild type mice. For each section, both ventralhorns were counted (total of 20 ventral horns per animal) and data arerepresented as average number of large motor neurons per ventral horn.Asterisks (*) denote statistically significant differences (P<0.001)between the indicated groups. Representative images from NISSL-stainedventral horn sections (20× magnification) are shown for (FIG. 6E andFIG. 6H) wild type mice treated with PBS, (FIG. 6F and FIG. 6I) SODG93Amice treated with PBS, and (FIG. 6G and FIG. 6J) SODG93A mice treatedwith RK35 analyzed at early (88 days) (FIG. 6E-FIG. 6G) and end-stagedisease (134 days; FIG. 6H-FIG. 6J). Bar denotes scale of 200 μm.

FIG. 7 is an image of a dot blot showing epitope mapping of GDF-8 forthe RK35 antibody. The binding sites on GDF-8 for RK35 were identifiedusing forty-eight (48) overlapping 13 amino acid peptides (13-mers) ofhuman GDF-8 (RK35 antibody binding to 13-mers 1 through 24 is shown inthe top row of the blot and RK35 binding to 13-mers 25-48 is shown inthe bottom row of the blot). FIG. 7 discloses amino acid residues 1-55(top row) and amino acid residues 56-109 (bottom row) of human GDF-8relative to SEQ ID NO: 1. The amino acid residue RK35 contact sites withGDF-8 are indicated in bold.

FIG. 8. Alignment of the light chain and heavy chain variable regions ofRK35 (VL and VH, respectively) with the human germline frameworks DPK9and DP-47, respectively. The alignment of the amino acid sequences ofthe VL regions of murine RK35 (MRK35 VL: SEQ ID NO:5). humanized RK35(HuRK35 VL: SEQ ID NO:9) and germline DPK-9 (SEQ ID NO:32) is shown. Thealignment of the amino acid sequences of the VH regions of murine RK35(mRK35 VH: SEQ ID NO:3), humanized RK35 (HuRK35 VH: SEQ ID NO:7) andgermline DP-47 (SEQ ID NO:33) is also shown. The amino acids of themurine RK35 (MRK35) variable chains that are changed in the humanizedRK35 (HuRK35) regions are designated with an asterisk (*) and are inbold; complementarity determining regions of RK35 are boxed andunderlined.

DETAILED DESCRIPTION OF THE INVENTION I. Definitions

“Antibody,” as used herein, refers to an immunoglobulin or a partthereof, and encompasses any polypeptide comprising an antigen-bindingsite regardless of the source, species of origin, method of production,and characteristics. For the purposes of the present invention, it alsoincludes, unless otherwise stated, antibody fragments such as Fab,F(ab′)₂, Fv, scFv, Fd, dAb, diabodies, and other antibody fragments thatretain antigen-binding function. Antibodies can be made, for example,via traditional hybridoma techniques, recombinant DNA methods, or phagedisplay techniques using antibody libraries. For various other antibodyproduction techniques, see Antibodies: A Laboratory Manual, eds. Harlowet al., Cold Spring Harbor Laboratory, 1988.

The term “antigen-binding domain” refers to the part of an antibodymolecule that comprises the area specifically binding to orcomplementary to a part or all of an antigen. Where an antigen is large,an antibody may only bind to a particular part of the antigen. The“epitope” or “antigenic determinant” is a portion of an antigen moleculethat is responsible for interactions with the antigen-binding domain ofan antibody. An antigen-binding domain may be provided by one or moreantibody variable domains (e.g., a so-called Fd antibody fragmentconsisting of a VH domain). An antigen-binding domain may comprise anantibody light chain variable region (VL) and an antibody heavy chainvariable region (VH).

The term “GDF-8” refers to a specific growth and differentiationfactor-8, but not other factors that are structurally or functionallyrelated to GDF-8, for example, BMP-11 and other factors belonging to theTGF-β superfamily. The term refers to the full-length unprocessedprecursor form of GDF-8 as well as the mature and propeptide formsresulting from post-translational cleavage. The term also refers to anyfragments and variants of GDF-8 that maintain at least some biologicalactivities associated with mature GDF-8, as discussed herein, includingsequences that have been modified. The amino acid sequence of maturehuman GDF-8 is provided in SEQ ID NO:1. The present invention relates toGDF-8 from all vertebrate species, including, but not limited to, human,bovine, chicken, mouse, rat, porcine, ovine, turkey, baboon, and fish(for sequence information, see, e.g., McPherron et al., supra).

The term “GDF-8 activity” refers to one or more of physiologicallygrowth-regulatory or morphogenetic activities associated with activeGDF-8 protein. For example, active GDF-8 is a negative regulator ofskeletal muscle mass. Active GDF-8 can also modulate the production ofmuscle-specific enzymes (e.g., creatine kinase), stimulate myoblastproliferation, and modulate preadipocyte differentiation to adipocytes.Exemplary procedures for measuring GDF-8 activity in vivo and in vitroare set forth in the Examples.

The term “GDF-8 antagonist” or “GDF-8 inhibitor” includes any agentcapable of inhibiting activity, expression, processing, or secretion ofGDF-8. Such inhibitors include macromolecules and small molecules, e.g.,proteins, antibodies, peptides, peptidomimetics, siRNA, ribozymes,antisense oligonucleotides, double-stranded RNA, and other smallmolecules, that inhibit GDF-8. A GDF-8 antagonist includes, in additionto the antibodies provided herein, any antibody that efficientlyinhibits GDF-8, including antibodies with high specificity for bindingto GDF-8 (e.g., antibodies with a low affinity for other members of theTGF-β superfamily (e.g., BMP-11)). Variants, including humanizedvariants, of these antibodies are contemplated in the methods ofdiagnosing, prognosing, monitoring, treating, ameliorating, andpreventing of the invention. Such inhibitors are said to “inhibit,”“decrease,” or “reduce” the biological activity of GDF-8.

The terms “neutralize,” “neutralizing,” and their cognates refer to adramatic reduction or abrogation of GDF-8 activity relative to theactivity of GDF-8 in the absence of the same inhibitor. For example, areduction of 75-100% of activity may be said to “neutralize” GDF-8activity.

The term “treatment” is used interchangeably herein with the term“therapeutic method” and refers to both therapeutic treatment andprophylactic/preventative measures. Those in need of treatment mayinclude individuals already having a particular medical disorder as wellas those who may ultimately acquire the disorder (i.e., those needingpreventive measures).

The term “isolated” refers to a molecule that is substantially separatedfrom its natural environment. For instance, an isolated protein is onethat is substantially separated from the cell or tissue source fromwhich it is derived.

The term “purified” refers to a molecule that is substantially free ofother material that associates with the molecule in its naturalenvironment. For instance, a purified protein is substantially free ofthe cellular material or other proteins from the cell or tissue fromwhich it is derived. The term refers to preparations where the isolatedprotein is sufficiently pure to be administered as a therapeuticcomposition, or at least 70% to 80% (w/w) pure, more preferably, atleast 80%-90% (w/w) pure, even more preferably, 90-95% pure; and, mostpreferably, at least 95%, 96%, 97%, 98%, 99%, or 100% (w/w) pure.

The term “effective dose,” “therapeutically effective dose,” “effectiveamount,” or the like refers to that amount of the compound that resultsin either amelioration of symptoms in a patient or a desired biologicaloutcome (e.g., increasing skeletal muscle mass and/or bone density).Such amount should be sufficient to reduce the activity of GDF-8associated with negative regulation of skeletal muscle mass and bonedensity or with glucose homeostasis and adipose metabolism. Theeffective amount can be determined as described herein.

A “disorder associated with GDF-8 activity,” “disorder associated withGDF-8,” “GDF-8-associated disorder” or the like refers to disorders thatmay be caused, in full or in part, by dysregulation of (e.g., abnormallyincreased or decreased) GDF-8 (and/or GDF-8 activity), and/or disordersthat may be treated, ameliorated, prevented, diagnosed, prognosed, ormonitored by regulating and/or monitoring GDF-8 (and/or GDF-8 activity).GDF-8-associated disorders include muscle disorders, neuromusculardisorders, bone degenerative disorders, metabolic or induced bonedisorders, adipose disorders, glucose metabolism disorders orinsulin-related disorders. A preferred GDF-8-associated disorder of theinvention is amyotrophic lateral sclerosis (ALS).

The term “small molecule” refers to compounds that are notmacromolecules (see, e.g., Karp (2000) Bioinformatics Ontology16:269-85; Verkman (2004) AJP-Cell Physiol. 286:465-74). Thus, smallmolecules are often considered those compounds that are less than onethousand daltons (e.g., Voet and Voet, Biochemistry, 2^(nd) ed., ed. N.Rose, Wiley and Sons, New York, 14 (1995)). For example, Davis et al.((2005) Proc. Natl. Acad. Sci. USA 102:5981-86) use the phrase smallmolecule to indicate folates, methotrexate, and neuropeptides, whileHalpin and Harbury ((2004) PLos Biology 2:1022-30) use the phrase toindicate small molecule gene products, e.g., DNAs, RNAs and peptides.Examples of natural small molecules include, but are not limited to,cholesterols, neurotransmitters, and siRNAs; synthesized small moleculesinclude, but are not limited to, various chemicals listed in numerouscommercially available small molecule databases, e.g., FCD (FineChemicals Database), SMID (Small Molecule Interaction Database), ChEBI(Chemical Entities of Biological Interest), and CSD (CambridgeStructural Database) (see, e.g., Alfarano et al. (2005) Nuc. Acids Res.Database Issue 33:D416-24).

II. Antibodies Against GDF-8 and Antibody Fragments

A. Mouse and Humanized Antibody RK35

The present disclosure provides novel antibodies (e.g., intactantibodies and antibody fragments) that efficiently bind GDF-8. Anonlimiting illustrative embodiment of such an antibody is termed RK35.This exemplary embodiment is provided in the form of mouse and humanizedantibodies, and antibody fragments thereof.

The exemplary antibody of the invention, referred to herein as “RK35,”possesses unique and beneficial characteristics. First, this antibodyand antibody fragments are capable of binding mature GDF-8 with highaffinity. Second, the antibody and antibody fragments of the inventioninhibit GDF-8 activity in vitro and in vivo as demonstrated, forexample, by inhibition of ActRIIB binding and reporter gene assays.Third, the disclosed antibody and antibody fragments are useful to treatsymptoms associated with a GDF-8-associated disorder, e.g., musculardisorders, particularly ALS, as demonstrated, e.g., by increasing musclemass in treated mutant SOD mice.

In an exemplary embodiment, GDF-8 antagonists are antibodies thatefficiently bind to GDF-8 and inhibit one or more GDF-8 associatedactivities. One of ordinary skill in the art will recognize that theantibodies of the invention may be used to detect, measure, and inhibitGDF proteins derived from various species, e.g., those described in thepresent specification. The percent identity is determined by standardalignment algorithms such as, for example, Basic Local Alignment Tool(BLAST) described in Altschul et al. (1990) J. Mol. Biol. 215:403-10,the algorithm of Needleman et al. (1970) J. Mol. Biol. 48:444-53, or thealgorithm of Meyers et al. (1988) Comput. Appl. Biosci. 4:11-17. Ingeneral, the antibody and antibody fragments of the invention can beused with any protein that retains substantial GDF-8 biological activityand comprises an amino acid sequence which is at least about 70%, 80%,90%, 95%, or more identical to any sequence of at least 100, 80, 60, 40,20, or 15 contiguous amino acids of the mature form of GDF-8 set forthin SEQ ID NO:1.

B. Antibody Variable Domains

Intact antibodies, also known as immunoglobulins, are typicallytetrameric glycosylated proteins composed of two light (L) chains ofapproximately 25 kDa each, and two heavy (H) chains of approximately 50kDa each. Two types of light chain, termed lambda and kappa, exist inantibodies. Depending on the amino acid sequence of the constant domainof heavy chains, immunoglobulins are assigned to five major classes: A,D, E, G, and M, and several of these may be further divided intosubclasses (isotypes), e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and IgA₂.Each light chain is composed of an N-terminal variable (V) domain (VL)and a constant (C) domain (CL). Each heavy chain is composed of anN-terminal V domain (VH), three or four C domains (CHs), and a hingeregion. The CH domain most proximal to VH is designated CHI. The VH andVL domains consist of four regions of relatively conserved sequencesnamed framework regions (FR1, FR2, FR3, and FR4), which form a scaffoldfor three regions of hypervariable sequences (complementaritydetermining regions, CDRs). The CDRs contain most of the residuesresponsible for interactions of the antibody with the antigen. CDRs arereferred to as CDR1, CDR2, and CDR3. Accordingly, CDR constituents onthe heavy chain are referred to as H1, H2, and H3, while CDRconstituents on the light chain are referred to as L1, L2, and L3. CDR3is the greatest source of molecular diversity within theantibody-binding site. H3, for example, can be as short as two aminoacid residues or greater than 26 amino acids. The subunit structures andthree-dimensional configurations of different classes of immunoglobulinsare well known in the art. For a review of the antibody structure, seeAntibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, eds.Harlow et al., 1988. One of skill in the art will recognize that eachsubunit structure, e.g., a CH, VH, CL, VL, CDR, and/or FR structure,comprises active fragments. For example, active fragments may consist ofthe portion of the VH, VL, or CDR subunit that binds the antigen, i.e.,the antigen-binding fragment, or the portion of the CH subunit thatbinds to and/or activates an Fc receptor and/or complement.

Nonlimiting examples of binding fragments encompassed within the term“antibody fragment” used herein include: (i) an Fab fragment, amonovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii)an F(ab′)₂ fragment, a bivalent fragment comprising two Fab fragmentslinked by a disulfide bridge at the hinge region; (iii) an Fd fragmentconsisting of the VH and CH1 domains; (iv) an Fv fragment consisting ofthe VL and VH domains of a single arm of an antibody, (v) a dAbfragment, which consists of a VH domain; and (vi) an isolated CDR.Furthermore, although the two domains of the Fv fragment, VL and VH, arecoded for by separate genes, they may be recombinantly joined by asynthetic linker, creating a single protein chain in which the VL and VHregions pair to form monovalent molecules (known as single chain Fv(scFv). The most commonly used linker is a 15-residue (Gly4Ser)3 (SEQ IDNO: 34) peptide, but other linkers are also known in the art. Singlechain antibodies are also intended to be encompassed within the term“antibody” or “antigen-binding fragment” of an antibody. Theseantibodies are obtained using conventional techniques known to thoseskilled in the art, and the fragments are screened for utility in thesame manner as intact antibodies.

Antibody diversity is created by multiple germline genes encodingvariable regions and a variety of somatic events. The somatic eventsinclude recombination of variable gene segments with diversity (D) andjoining (J) gene segments to make a complete VH region, and therecombination of variable and joining gene segments to make a completeVL region. The recombination process itself is imprecise, resulting inthe loss or addition of amino acids at the V(D)J junctions. Thesemechanisms of diversity occur in the developing B cell prior to antigenexposure. After antigenic stimulation, the expressed antibody genes in Bcells undergo somatic mutation. Based on the estimated number ofgermline gene segments, the random recombination of these segments, andrandom VH-VL pairing, up to 1.6×10⁷ different antibodies may be produced(Fundamental Immunology, 3rd ed. (1993), ed. Paul, Raven Press, NewYork, N.Y.). When other processes that contribute to antibody diversity(such as somatic mutation) are taken into account, it is thought thatupwards of 1×10¹⁰ different antibodies may be generated (ImmunoglobulinGenes, 2nd ed. (1995), eds. Jonio et al., Academic Press, San Diego,Calif.). Because of the many processes involved in generating antibodydiversity, it is unlikely that independently derived monoclonalantibodies with the same antigen specificity will have identical aminoacid sequences.

Thus, the present invention provides novel antibodies that bind GDF-8.The antibody fragments of the invention, e.g., structures containing aCDR, will generally be an antibody heavy or light chain sequence, or anactive fragment thereof, in which the CDR is placed at a locationcorresponding to the CDR of naturally occurring VH and VL. Thestructures and locations of immunoglobulin variable domains, e.g., CDRs,may be defined using well-known numbering schemes, e.g., the Kabatnumbering scheme, the Chothia numbering scheme, a combination of Kabatand Chothia (AbM), etc. (see, e.g., Sequences of Proteins ofImmunological Interest, U.S. Department of Health and Human Services(1991), eds. Kabat et al.; Al-Lazikani et al. (1997) J. Mol. Biol.273:927-48).

Thus, the present invention further provides novel CDRs. The structurefor carrying a CDR of the invention will generally be a polypeptide,e.g., an antibody heavy or light chain sequence or a substantial portionthereof, in which the CDR is located at a position corresponding to theCDR of naturally occurring VH and VL regions. The structures andlocations of immunoglobulin variable domains may be determined asdescribed in, e.g., Kabat et al., supra and Al-Lazikani et al., supra.

Antibody molecules (including antibody fragments) of the presentinvention, i.e., antibody molecules that antagonize GDF-8, include, butare not limited to, murine monoclonal antibody RK35 and its variants,specifically the humanized variant. GDF-8 antagonists of the inventioninclude, in addition to RK35, other antibodies that bind efficiently toGDF-8, including antibodies with high specificity for binding to GDF-8(e.g., antibodies with a lower affinity for other members of the TGF-βsuperfamily (e.g., BMP-11)). Variants, including humanized variants, ofthese antibodies are contemplated in the methods of diagnosing,prognosing, monitoring, treating, ameliorating, and preventing of theinvention. These antibody molecules may be useful in preventing ortreating a GDF-8-associated disorder, e.g., bone, muscle, adipose andglucose metabolism-related pathologies. The amino acid sequences of thelight chain variable regions of murine and humanized RK35 are set forthin SEQ ID NOs:5 and 9, respectively. The amino acid sequences of theheavy chain variable regions of murine and humanized RK35 are set forthin SEQ ID NOs:3 and 7, respectively. The amino acid sequences of thethree complementarity determining regions (CDRs) in the variable lightchains of murine and humanized RK35 are set forth in SEQ ID NOs:13, 14,15, 23, 24, and 25. The amino acid sequences of the three CDRs in thevariable heavy chains of murine and humanized RK35 are set forth in SEQID NOs:10, 11, 12, 20, 21, and 22.

As described above, the CDRs contain most of the residues responsiblefor interactions with an antigen, and are contained within the VH and VLdomains, i.e., the heavy chain variable region and the light chainvariable region, respectively. Consequently, provided that an antibodycomprises at least one CDR comprising an amino acid sequence selectedfrom the amino acid sequences set forth in SEQ ID NOs:10-15 and 20-25,or an active antibody fragment thereof, it is an antibody of theinvention, i.e., one that binds to GDF-8 and interferes with GDF-8signaling. Therefore, an embodiment of the invention includespolypeptides, e.g., antibodies, that contain one or more CDRs thatcomprise an amino acid sequence selected from the amino acid sequencesset forth in SEQ ID NOs:10-15 and 20-25, or an active fragment thereof.Consequently, one of skill in the art will recognize that the antibodiesof the invention include an antibody in which the CDRs of the VL chainare those set forth in SEQ ID NOs:13-15 and 23-25, or the CDRs of the VHchain are those set forth in SEQ ID NOs:10-12 and 20-22.

An antigen-binding fragment may be an Fv fragment, which consists of VHand VL domains. Thus, an Fv fragment of RK35 may constitute an antibodyof the invention, provided that it binds to GDF-8 and interferes withGDF-8 signaling. One of skill in the art will recognize that anyantibody fragment containing the Fv fragment of, e.g., RK35, may also bean antibody of the invention. Additionally, any Fv fragment, scFvfragment, Fab fragment, or F(ab′)₂ fragment, that contains one or moreCDRs having an amino acid sequence selected from the amino acidsequences set forth in SEQ ID NOs:10-15 and 20-25, may also be anantibody of the invention.

Such antibody molecules may be produced by methods well known to thoseskilled in the art. For example, monoclonal antibodies may be producedby generation of hybridomas in accordance with known methods. Hybridomasformed in this manner are then screened using standard methods, such asenzyme-linked immunosorbent assay (ELISA) and Biacore analysis, toidentify one or more hybridomas that produce an antibody that bindsGDF-8, interferes with GDF-8 signaling, and neutralizes or inhibits oneor more GDF-8-associated activities. Recombinant GDF-8, naturallyoccurring GDF-8, any variants thereof, and antigenic peptide fragmentsof GDF-8 may be used as the immunogen. An antigenic peptide fragment ofGDF-8 comprises at least seven continuous amino acid residues andencompasses an epitope such that an antibody raised against the peptideforms an immune complex with GDF-8. Preferably, the antigenic peptidecomprises at least 10 amino acid residues, more preferably at least 15amino acid residues, even more preferably at least 20 amino acidresidues, and most preferably at least 30 amino acid residues.Additionally, it is preferable that the antigenic peptide fragment ofGDF-8 comprises the GDF-8 receptor-binding site.

Polyclonal sera and antibodies of the invention may be produced byimmunizing a suitable subject with GDF-8, its variants, and/or portionsthereof. The antibody titer in the immunized subject may be monitoredover time by standard techniques, such as an ELISA, or by usingimmobilized GDF-8 or other marker proteins (e.g., FLAG). If desired, theantibody molecules of the present invention may be isolated from thesubject or culture media and further purified by well-known techniques,such as protein A chromatography, to obtain an IgG fraction.

Certain embodiments of the invention comprise the VH and/or VL domain ofthe Fv fragment of RK35. Fragments of antibodies of the presentinvention, e.g., Fab, F(ab′)₂, Fd, and dAb fragments, may be produced bycleavage of the antibodies in accordance with methods well known in theart. For example, immunologically active Fab and F(ab′)₂ fragments maybe generated by treating the antibodies with an enzyme such as papainand pepsin.

Further embodiments comprise one or more CDRs of any of these VH and VLdomains, as set forth in SEQ ID NOs:10-15 and 20-25. One embodimentcomprises an H3 fragment of the VH domain of RK35 as set forth in SEQ IDNO:12.

DNA and amino acid (AA) sequences of VH and VL domains, and CDRs of thepresently disclosed antibodies are enumerated as listed in Table 1. Forconvenience, the approximate positions of each CDR within the VH and VLdomains are listed in Table 2.

TABLE 1 DNA and Amino Acid Sequences of VH, VL, CH, CL and CDRs in RK35MOUSE DNA seq.of VH SEQ ID NO: 2 AA seq. of VH SEQ ID NO: 3 DNA seq. ofVL SEQ ID NO: 4 AA seq. of VL SEQ ID NO: 5 HUMANIZED DNA seq. of VH SEQID NO: 6 AA seq. of VH SEQ ID NO: 7 DNA seq. of VL SEQ ID NO: 8 AA seq.of VL SEQ ID NO: 9 CDRs BASED AA sequence of SEQ ID NO: 10 or SEQ ID NO:20 ON KABAT H1 OR AbM (ital) AA sequence of SEQ ID NO: 11 or SEQ ID NO:21 DEFINITIONS H2 AA sequence of SEQ ID NO: 12 or SEQ ID NO: 22 H3 AAsequence of SEQ ID NO: 13 or SEQ ID NO: 23 L1 AA sequence of SEQ ID NO:14 or SEQ ID NO: 24 L2 AA sequence of SEQ ID NO: 15 or SEQ ID NO: 25 L3DNA seq. of CL SEQ ID NO: 16 AA seq. of CL SEQ ID NO: 17 DNA seq. of CHSEQ ID NO: 18 AA seq. of CH SEQ ID NO: 19

TABLE 2 Approximate CDR position according to Kabat (not ital.) or AbM(ital.) definitions within variable regions of RK35 mouse and humanizedantibodies RIGS RK35 CDR SEQ ID NO: 3 SEQ ID NO: 7 HI 31-35 or 26-3531-35 or 26-35 H2 50-66 or 50-59 50-66 or 50-59 H3 99-105 or 99-10599-105 or 99-105 SEQ ID NO: 5 SEQ ID NO: 9 LI 24-34 or 24-34 24-34 or24-34 L2 50-56 or 50-56 50-56 or 50-56 L3 89-95 or 89-95 89-95 or 89-95

Anti-GDF-8 antibodies may further comprise antibody constant regions orparts thereof. For example, a VL domain of the invention may be attachedat its C-terminal end to an antibody light chain constant domain, e.g.,a human Cκ or Cλ chain, preferably a Cλ chain. Similarly, anantigen-binding fragment based on a VH domain may be attached at itsC-terminal end to all or part of an immunoglobulin heavy chain derivedfrom any antibody isotype, e.g., IgG, IgA, IgE, and IgM, and any of theisotype subclasses, particularly IgG₁ and IgG₄. In exemplaryembodiments, antibodies comprise C-terminal fragments of heavy and lightchains of human IgG_(1λ). Preferred DNA and amino acid sequences for theC-terminal constant fragment of the light λ chain are set forth in SEQID NO:16 and SEQ ID NO:17, respectively. Preferred DNA and amino acidsequences for the C-terminal constant fragment of IgG₁ heavy chain areset forth in SEQ ID NO:18 and SEQ ID NO:19, respectively. It isunderstood that, due to the degeneracy of the genetic code, DNAsequences listed in Table 1 are merely representative of nucleic acidsthat encode the amino acid sequences, peptides, and antibodies ofinterest, and are not to be construed as limiting.

Certain embodiments of the invention comprise the VH and/or VL domain ofthe Fv fragment of RK35. Further embodiments comprise one or morecomplementarity determining regions (CDRs) of any of these VH and VLdomains. One embodiment comprises an H3 fragment of the VH domain ofRK35. The VH and VL domains of the invention, in certain embodiments,are germlined, i.e., the framework regions (FRs) of these domains arechanged using conventional molecular biology techniques to match theconsensus amino acid sequences of human germline gene products. This isalso known as a humanized or germlined antibody. In other embodiments,the framework sequences remain diverged from the germline. Humanizedantibodies may be produced using transgenic mice that are incapable ofexpressing endogenous immunoglobulin heavy and light chain genes, butare capable of expressing human heavy and light chain genes.

C. Modified Antibodies and their Fragments

A further aspect of the invention provides methods for obtaining anantibody antigen-binding domain directed against GDF-8. The skilledartisan will appreciate that the antibodies of the invention are notlimited to the specific sequences of VH and VL as listed in Table 1 butalso include variants of these sequences that retain antigen-bindingability. Such variants may be derived from the provided sequences usingtechniques known in the art. Amino acid substitutions, deletions, oradditions, can be made in either the FRs or in the CDRs. While changesin the framework regions are usually designed to improve stability andreduce immunogenicity of the antibody, changes in the CDRs are usuallydesigned to increase affinity of the antibody for its target. Suchaffinity-increasing changes are typically determined empirically byaltering the CDR and testing the antibody. Such alterations can be madeaccording to the methods described in, e.g., Antibody Engineering, 2nd.ed., Borrebaeck, ed., Oxford University Press, 1995.

Thus, the antibodies of the invention also include those that bind toGDF-8, interfere with GDF-8 signaling, and have mutations in theconstant regions of the heavy and light chains. It is sometimesdesirable to mutate and inactivate certain fragments of the constantregion. For example, mutations in the heavy constant region aresometimes desirable to produce antibodies with reduced binding to the Fcreceptor (FcR) and/or complement; such mutations are well known in theart. One of skill in the art will also recognize that the determinationof which active fragments of the CL and CH subunits are necessary willdepend on the application to which an antibody of the invention isapplied. For example, the active fragments of the CL and CH subunitsthat are involved with their covalent link to each other will beimportant in the generation of an intact antibody.

The method for making a VH domain that is an amino acid sequence variantof a VH domain set out herein comprises a step of adding, deleting,substituting or inserting one or more amino acids in the amino acidsequence of the presently disclosed VH domain, optionally combining theVH domain thus provided with one or more VL domains, and testing the VHdomain or VH/VL combination or combinations for binding to GDF-8, and(preferably) testing the ability of such antigen-binding domain tomodulate one or more GDF-8-associated activities. The VL domain may havean amino acid sequence that is substantially as set out herein. Ananalogous method may be employed in which one or more sequence variantsof a VL domain disclosed herein are combined with one or more VHdomains.

A further aspect of the invention provides a method of preparing anantigen-binding fragment that interacts with GDF-8. The methodcomprises:

(a) providing a starting repertoire of nucleic acids encoding a VHdomain that either includes a CDR, e.g., CDR3, to be replaced or a VHdomain that lacks a CDR, e.g., CDR3, encoding region;

(b) combining the repertoire with a donor nucleic acid encoding a donorCDR comprising an active fragment of SEQ ID NO:2 or 6, e.g., a donornucleic acid encoding the amino acid sequence set forth in SEQ ID NO:3or 7, such that the donor nucleic acid is inserted into the CDR, e.g.,CDR3, region in the repertoire so as to provide a product repertoire ofnucleic acids encoding a VH domain;

(c) expressing the nucleic acids of the product repertoire;

(d) selecting an antigen-binding fragment that interacts with GDF-8; and

(e) recovering the selected antigen-binding fragment or nucleic acidencoding it.

Again, an analogous method may be employed in which a VL CDR (e.g., L3)of the invention is combined with a repertoire of nucleic acids encodinga VL domain, which either includes a CDR to be replaced or lacks a CDRencoding region.

A coding sequence of a CDR of the invention (e.g., CDR3) may beintroduced into a repertoire of variable domains lacking a CDR (e.g.,CDR3), using recombinant DNA technology. For example, Marks et al.(1992) Bio/Technology 10:779-83, describes methods of producingrepertoires of antibody variable domains in which consensus primersdirected at or adjacent to the 5′ end of the variable domain area areused in conjunction with consensus primers to the third framework regionof human VH genes to provide a repertoire of VH variable domains lackinga CDR3. The repertoire may be combined with a CDR3 of a particularantibody. Using analogous techniques, the CDR3-derived sequences of thepresent invention may be shuffled with repertoires of VH or VL domainslacking a CDR3, and the shuffled complete VH or VL domains combined witha cognate VL or VH domain to provide antigen-binding fragments of theinvention. The repertoire may then be displayed in a suitable hostsystem, such as the phage display system of, e.g., WO 92/01047, so thatsuitable antigen-binding fragments can be selected.

Analogous shuffling or combinatorial techniques are also disclosed byStemmer (1994) Nature 370:389-91, which describes a technique inrelation to a β-lactamase gene but observes that the approach may beused for the generation of antibodies.

A further alternative is to generate novel VH or VL regions carrying aCDR-derived sequence of the invention using random mutagenesis of one ormore selected VH and/or VL genes to generate mutations within the entirevariable domain. Such a technique is described in Gram et al. (1992)Proc. Natl. Acad. Sci. U.S.A. 89:3576-80 by using error-prone PCR.

Another method that may be used to generate novel antibodies orfragments thereof is to direct mutagenesis to CDRs of VH or VL genes.Such techniques are disclosed in Barbas et al. (1994) Proc. Natl. Acad.Sci. U.S.A. 91:3809-13 and Schier et al. (1996) J. Mol. Biol.263:551-67.

Similarly, one, two, or all three CDRs, may be grafted into a repertoireof VH or VL domains which are then screened for a binding partner orbinding fragments for GDF-8.

A substantial portion of an immunoglobulin variable domain will compriseat least the CDRs and, optionally, their intervening framework regionsfrom the antibody fragments as set out herein. The portion will alsoinclude at least about 50% of either or both of FR1 and FR4, the 50%being the C-terminal 50% of FR1 and the N-terminal 50% of FR4.Additional residues at the N-terminal or C-terminal end of thesubstantial part of the variable domain may be those not normallyassociated with naturally occurring variable domain regions. Forexample, construction of antibody fragments of the present inventionmade by recombinant DNA techniques may result in the introduction of N-or C-terminal residues encoded by linkers introduced to facilitatecloning or other manipulation steps. Other manipulation steps includethe introduction of linkers to join variable domains of the invention tofurther protein sequences including immunoglobulin heavy chains, othervariable domains (for example, in the production of diabodies) orprotein labels as discussed in more details below.

Although the embodiments illustrated in the Examples comprise a“matching” pair of VH and VL domains, the invention also encompassesbinding fragments containing a single variable domain, e.g., a dAbfragment, derived from either VH or VL domain sequences, especially VHdomains. In the case of either of the single chain binding domains,these domains may be used to screen for complementary domains capable offorming a two-domain antigen-binding domain capable of binding GDF-8.This may be achieved by phage display screening methods using theso-called hierarchical dual combinatorial approach as disclosed in,e.g., WO 92/01047. In this technique, an individual colony containingeither an H or L chain clone is used to infect a complete library ofclones encoding the other chain (L or H) and the resulting two-chainantigen-binding domain is selected in accordance with phage displaytechniques, such as those described in that reference. This technique isalso disclosed in Marks et al., supra.

Antibodies can be conjugated by chemical methods with radionuclides,drugs, macromolecules, or other agents, and may be made as fusionproteins comprising one or more CDRs of the invention.

An antibody fusion protein contains a VH-VL pair in which one of thesechains (usually VH) and another protein are synthesized as a singlepolypeptide chain. These types of products differ from antibodies inthat they generally have an additional functional element—the activemoiety of a small molecule or the principal molecular structural featureof the conjugated or fused macromolecule.

In addition to the changes to the amino acid sequence outlined above,the antibodies can be glycosylated, pegylated, or linked to albumin or anonproteinaceous polymer. For instance, anti-GDF-8 antibodies may belinked to one of a variety of nonproteinaceous polymers, e.g.,polyethylene glycol, polypropylene glycol, or polyoxyalkylenes. Theantibodies may be chemically modified, e.g., to increase theircirculating half-life by covalent conjugation to a polymer. Exemplarypolymers, and methods to attach them to peptides are known in the art.

In other embodiments, the antibody may be modified to have an alteredglycosylation pattern (i.e., relative to the original or nativeglycosylation pattern). As used herein, “altered” means having one ormore carbohydrate moieties deleted, and/or having one or moreglycosylation sites added to the original antibody. Addition ofglycosylation sites to an anti-GDF-8 antibody is accomplished bywell-known methods of altering the amino acid sequence to containglycosylation site consensus sequences. Another means of increasing thenumber of carbohydrate moieties on the antibodies is by chemical orenzymatic coupling of glycosides to the amino acid residues of theantibody. Removal of any carbohydrate moieties present on the antibodiesmay be accomplished chemically or enzymatically as known in the art.

Antibodies of the invention may also be tagged with a detectable orfunctional label such as ¹³¹I or ⁹⁹Tc, which may be attached toantibodies of the invention using conventional chemistry known in theart. Labels also include enzyme labels such as horseradish peroxidase oralkaline phosphatase. Labels further include chemical moieties such asbiotin, which may be detected via binding to a specific cognatedetectable moiety, e.g., labeled avidin.

Antibodies, in which CDR sequences differ only insubstantially fromthose listed in Table 1, are encompassed within the scope of theinvention. Insubstantial differences include minor amino acid changes,e.g., substitutions of one or two out of any five amino acids in thesequence of a CDR. Typically, an amino acid is substituted by a relatedamino acid having similar charge, hydrophobicity, or stereochemicalcharacteristics. Such substitutions would be within the ordinary skillsof an artisan. The structure framework regions (FRs) can be modifiedmore substantially than CDRs without adversely affecting the bindingproperties of an antibody. Changes to FRs include, but are not limitedto, humanizing a nonhuman derived framework or engineering certainframework residues that are important for antigen contact or forstabilizing the binding site, e.g., changing the class or subclass ofthe constant region, changing specific amino acid residues which mightalter an effector function such as Fc receptor binding (e.g., Lund etal. (1991) J. Immunol. 147:2657-62; Morgan et al. (1995) Immunology86:319-24), or changing the species from which the constant region isderived. Antibodies may have mutations in the CH2 region of the heavychain that reduce or alter effector function, e.g., Fc receptor bindingand complement activation. For example, antibodies may have mutationssuch as those described in U.S. Pat. Nos. 5,624,821 and 5,648,260. Inthe IgG₁ or IgG₂ heavy chain, for example, such mutations may be made atamino acid residues 117 and 120 of SEQ ID NO:19, which represents the Fcportion of IgG₁ (these residues correspond to amino acids 234 and 237 inthe full-length sequence of IgG₁ or IgG₂). Antibodies may also havemutations that stabilize the disulfide bond between the two heavy chainsof an immunoglobulin, such as mutations in the hinge region of IgG₄, asdisclosed in, e.g., Angal et al. (1993) Mol. Immunol. 30:105-08.

The polypeptides and antibodies of the present invention also encompassproteins that are structurally different from the disclosed polypeptidesand antibodies, e.g., which have an altered sequence but substantiallythe same biochemical properties as the disclosed polypeptides andantibodies, e.g., have changes only in functionally nonessential aminoacids. Such molecules include naturally occurring allelic variants anddeliberately engineered variants containing alterations, substitutions,replacements, insertions, or deletions. Techniques for such alterations,substitutions, replacements, insertions, or deletions are well known tothose skilled in the art.

Antibodies of the invention may additionally be produced usingtransgenic nonhuman animals that are modified so as to produce fullyhuman antibodies rather than the animal's endogenous antibodies inresponse to challenge by an antigen. See, e.g., PCT publication WO94/02602. The endogenous genes encoding the heavy and lightimmunoglobulin chains in the nonhuman host have been incapacitated, andactive loci encoding human heavy and light chain immunoglobulins areinserted into the host's genome. The human genes are incorporated, forexample, using yeast artificial chromosomes containing the requisitehuman DNA segments. An animal which provides all the desiredmodifications is then obtained as progeny by crossbreeding intermediatetransgenic animals containing fewer than the full complement of themodifications. One embodiment of such a nonhuman animal is a mouse, andis termed the XENOMOUSE™ as disclosed in PCT publications WO 96/33735and WO 96/34096. This animal produces B cells that secrete fully humanimmunoglobulins. The antibodies can be obtained directly from the animalafter immunization with an immunogen of interest, as, for example, apreparation of a polyclonal antibody, or alternatively from immortalizedB cells derived from the animal, such as hybridomas producing monoclonalantibodies. Additionally, the genes encoding the immunoglobulins withhuman variable regions can be recovered and expressed to obtain theantibodies directly, or can be further modified to obtain analogs ofantibodies such as, for example, single chain Fv molecules.

Consequently, the term antibody as used herein includes intactantibodies, fragments of antibodies, e.g., Fab, F(ab′)₂, Fd, dAb andscFv fragments, and intact antibodies and fragments that have beenmutated either in their constant and/or variable regions (e.g.,mutations to produce chimeric, partially humanized, or fully humanizedantibodies, as well as to produce antibodies with a desired trait, e.g.,enhanced GDF-8 binding and/or reduced FcR binding). As such theseantibodies are included in the scope of the invention, provided that theantibody binds specifically to GDF-8, interferes with GDF-8 signaling,and/or neutralizes or inhibits one or more GDF-8-associated activities.

Other protein-binding molecules may also be employed to modulate theactivity of GDF-8. Such protein-binding molecules include small modularimmunopharmaceutical (SMIP™) drugs (Trubion Pharmaceuticals, Seattle,Wash.). SMIPs are single-chain polypeptides composed of a binding domainfor a cognate structure such as an antigen, a counterreceptor or thelike, a hinge-region polypeptide having either one or no cysteineresidues, and immunoglobulin CH2 and CH3 domains (see alsowww.trubion.com). SMIPs and their uses and applications are disclosedin, e.g., U.S. Published Patent Appln. Nos. 2003/0118592, 2003/0133939,2004/0058445, 2005/0136049, 2005/0175614, 2005/0180970, 2005/0186216,2005/0202012, 2005/0202023, 2005/0202028, 2005/0202534, and2005/0238646, and related patent family members thereof, all of whichare hereby incorporated by reference herein in their entireties.

The binding capacity of an antibody of the invention may be measured bythe following methods: Biacore analysis, enzyme linked immunosorbentassay (ELISA), X-ray crystallography, sequence analysis and scanningmutagenesis as described in the Examples below, and other methods thatare well known in the art. The ability of an antibody of the inventionto neutralize and/or inhibit one or more GDF-8-associated activities maybe measured by the following nonlimiting list of methods: assays formeasuring the proliferation of a GDF-8-dependent cell line; assays formeasuring the expression of GDF-8-mediated polypeptides; assaysmeasuring the activity of downstream signaling molecules; assays testingthe efficiency of an antibody of the invention to prevent muscledisorders in a relevant animal model; assays as described in theExamples below; and other assays that are well known in the art.

A further aspect of the invention provides a method of selectingantibodies capable of binding GDF-8 and neutralizing and/or inhibitingone or more GDF-8-associated activities. The method comprises:

a) contracting a plurality of antibodies with GDF-8;

b) choosing antibodies that bind to GDF-8;

c) testing the ability of chosen antibodies to prevent GDF-8 frombinding to the GDF-8 receptor; and

d) selecting antibodies capable of preventing GDF-8 from binding to itsreceptor.

The anti-GDF-8 antibodies of the invention are also useful forisolating, purifying, and/or detecting GDF-8 in supernatants, cellularlysates, or on a cell surface. Antibodies disclosed in this inventioncan be used diagnostically to monitor GDF-8 protein levels as part of aclinical testing procedure. Additionally, antibodies of the inventioncan be used in treatments requiring the neutralization and/or inhibitionof one or more GDF-8-associated activities, e.g., treatments for ALS andother muscle-related pathologies. The present invention also providesnovel isolated and purified polynucleotides and polypeptides related tonovel antibodies directed against human GDF-8. The genes,polynucleotides, proteins, and polypeptides of the present inventioninclude, but are not limited to, murine and humanized antibodies toGDF-8 (e.g., RK35) and variants thereof.

D. Nucleic Acids, Cloning and Expression Systems

The present invention further provides isolated and purified nucleicacids encoding antibodies of the present invention. Nucleic acidsaccording to the present invention may comprise DNA or RNA and may bewholly or partially synthetic. Reference to nucleotide sequences as setout herein encompass DNA molecules with the specified sequences orgenomic equivalents, as well as RNA molecules with the specifiedsequences in which U is substituted for T, unless context requiresotherwise.

For example, the invention provides purified and isolatedpolynucleotides encoding the variable region of a murine antibody toGDF-8 that modulates one or more GDF-8-associated activities (e.g.,neutralizes GDF-8 bioactivity) (RK35), and a humanized version of RK35.Preferred DNA sequences of the invention include genomic, cDNA, andchemically synthesized DNA sequences.

The nucleotide sequences of the invention include those that encode thelight chain variable regions of mouse RK35 set forth in SEQ ID NO:4,including those that encode a leader sequence preceding the light chainvariable region sequence, e.g., the nucleotide sequence set forth as SEQID NO:30 (nucleotides 1-60 correspond to the leader sequence, andnucleotides 61-381 correspond to SEQ ID NO:4). The nucleotide sequencesof the invention also include those that encode the heavy chain variableregion of RK35 set forth in SEQ ID NO:2, including those that encode aleader sequence preceding the heavy chain variable region, e.g., thenucleotide sequence set forth as SEQ ID NO:28 (nucleotides 1-57correspond to the leader sequence, and nucleotides 58-405 correspond toSEQ ID NO:2). The nucleotide sequences of the invention also includehumanized sequences of the heavy and light chain variable regions, suchas those set forth in SEQ ID NOs:6 and 8, respectively. Polynucleotidesof the present invention also include polynucleotides that hybridizeunder stringent conditions to the nucleic acid sequences set forth inSEQ ID NOs:2, 4, 6, and 8, and complements thereof, and/or encodepolypeptides that retain substantial biological activity (i.e., activefragments) in the variable regions. Polynucleotides of the presentinvention also include continuous portions of the sequences set forth inSEQ ID NOs:2, 4, 6, and 8, comprising at least 15 consecutivenucleotides.

The amino acid sequence of the variable light chains of mouse RK35 isset forth in SEQ ID NO:5. An example of an amino acid sequence of thevariable light chain domain of mouse RK35 preceded by a leader sequenceis set forth as SEQ ID NO:31. The amino acid sequence of the variableheavy chains of RK35 is set forth in SEQ ID NO:3. An example of an aminoacid sequence of the variable heavy chain domain of mouse RK35 precededby a leader sequence is set forth as SEQ ID NO:29. The amino acidsequences of humanized variable heavy and light chains are set out inSEQ ID NOs:7 and 9, respectively. The amino acid sequences of the CDRscontained within the heavy chains of mouse RK35 are set forth in SEQ IDNOs:10-12 and 20-22. The amino acid sequences of the CDRs containedwithin the light chains of mouse RK35 are set forth in SEQ ID NOs:13-15and 23-25. Polypeptides of the present invention also include continuousportions of any of the sequences substantially set forth in SEQ IDNOs:3, 5, 7, 9, 10-15, and 20-25 comprising at least 5 consecutive aminoacids. A preferred polypeptide of the present invention includes anycontinuous portion of any sequence substantially set forth in SEQ IDNOs:3, 5, 7, 9, and 10-15 retaining substantial biological activity ofan antibody of the invention. In addition to those polynucleotidesdescribed above, the present invention also includes polynucleotidesthat encode the amino acid sequences substantially set forth in SEQ IDNOs:3, 5, 7, 9, and 10-15 or a continuous portion thereof, and thatdiffer from the polynucleotides described above only due to thewell-known degeneracy of the genetic code.

The isolated polynucleotides of the present invention may be used ashybridization probes and primers to identify and isolate nucleic acidshaving sequences identical to or similar to those encoding the disclosedpolynucleotides. Polynucleotides isolated in this fashion may be used,for example, to produce antibodies against GDF-8 or other TGF-β familymembers or to identify cells expressing such antibodies. Hybridizationmethods for identifying and isolating nucleic acids include polymerasechain reaction (PCR), Southern hybridizations, in situ hybridization andNorthern hybridization, and are well known to those skilled in the art.

Hybridization reactions can be performed under conditions of differentstringencies. The stringency of a hybridization reaction includes thedifficulty with which any two nucleic acid molecules will hybridize toone another. Preferably, each hybridizing polynucleotide hybridizes toits corresponding polynucleotide under reduced stringency conditions,more preferably stringent conditions, and most preferably highlystringent conditions. Examples of stringency conditions are shown inTable 3 below: highly stringent conditions are those that are at leastas stringent as, for example, conditions A-F; stringent conditions areat least as stringent as, for example, conditions G-L; and reducedstringency conditions are at least as stringent as, for example,conditions M-R.

TABLE 3 Hybridization Hybrid Length Temperature and Wash TemperatureCondition Hybrid (bp)¹ Buffer² and Buffer² A DNA:DNA >50 65° C.; 1X SSC-or- 65° C.; 0.3X SSC 42° C.; 1X SSC, 50% formamide B DNA:DNA <50T_(B)*; 1X SSC T_(B)*; 1X SSC C DNA:RNA >50 67° C.; 1X SSC -or- 67° C.;0.3X SSC 45° C.; 1X SSC, 50% formamide D DNA:RNA <50 T_(D)*; 1X SSCT_(D)*; 1X SSC E RNA:RNA >50 70° C.; 1X SSC -or- 70° C.; 0.3X SSC 50°C.; 1X SSC, 50% formamide F RNA:RNA <50 T_(F)*; 1X SSC T_(F)*; 1X SSC GDNA:DNA >50 65° C.; 4X SSC -or- 65° C.; 1X SSC 42° C.; 4X SSC, 50%formamide H DNA:DNA <50 T_(H)*; 4X SSC T_(H)*; 4X SSC I DNA:RNA >50 67°C.; 4X SSC -or- 67° C.; 1X SSC 45° C.; 4X SSC, 50% formamide J DNA:RNA<50 T_(J)*; 4X SSC T_(J)*; 4X SSC K RNA:RNA >50 70° C.; 4X SSC -or- 67°C.; 1X SSC 50° C.; 4X SSC, 50% formamide L RNA:RNA <50 T_(L)*; 2X SSCT_(L)*; 2X SSC M DNA:DNA >50 50° C.; 4X SSC -or- 50° C.; 2X SSC 40° C.;6X SSC, 50% formamide N DNA:DNA <50 T_(N)*; 6X SSC T_(N)*; 6X SSC ODNA:RNA >50 55° C.; 4X SSC -or- 55° C.; 2X SSC 42° C.; 6X SSC, 50%formamide P DNA:RNA <50 T_(P)*; 6X SSC T_(P)*; 6X SSC Q RNA:RNA >50 60°C.; 4X SSC -or- 60° C.; 2X SSC 45° C.; 6X SSC, 50% formamide R RNA:RNA<50 T_(R)*; 4X SSC T_(R)*; 4X SSC ¹The hybrid length is that anticipatedfor the hybridized region(s) of the hybridizing polynucleotides. Whenhybridizing a polynucleotide to a target polynucleotide of unknownsequence, the hybrid length is assumed to be that of the hybridizingpolynucleotide. When polynucleotides of known sequence are hybridized,the hybrid length can be determined by aligning the sequences of thepolynucleotides and identifying the region or regions of optimalsequence complementarity. ²SSPE (1xSSPE is 0.15M NaCl, 10 mM NaH₂PO₄,and 1.25 mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15MNaCl and 15 mM sodium citrate) in the hybridization and wash buffers;washes are performed for 15 minutes after hybridization is complete.T_(B)*-T_(R)*: The hybridization temperature for hybrids anticipated tobe less than 50 base pairs in length should be 5-10° C. less than themelting temperature (T_(m)) of the hybrid, where Tm is determinedaccording to the following equations. For hybrids less than 18 basepairs in length, T_(m) (° C.) = 2(# of A + T bases) + 4(# of G + Cbases). For hybrids between 18 and 49 base pairs in length, T_(m) (° C.)= 81.5 + 16.6(log₁₀Na⁺) + 0.41(% G + C) − (600/N), where N is the numberof bases in the hybrid, and Na⁺is the concentration of sodium ions inthe hybridization buffer (Na⁺for 1X SSC = 0.165M). Additional examplesof stringency conditions for polynucleotide hybridization are providedin Sambrook et al., Molecular Cloning: A Laboratory Manual, Chs. 9 & 11,Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989), andAusubel et al., eds., Current Protocols in Molecular Biology, Sects.2.10 & 6.3-6.4, John Wiley & Sons, Inc. (1995), herein incorporated byreference.

The isolated polynucleotides of the present invention may be used ashybridization probes and primers to identify and isolate DNAs havingsequences encoding allelic variants of the disclosed polynucleotides.Allelic variants are naturally occurring alternative forms of thedisclosed polynucleotides that encode polypeptides that are identical toor have significant similarity to the polypeptides encoded by thedisclosed polynucleotides. Preferably, allelic variants have at least90% sequence identity (more preferably, at least 95% identity; mostpreferably, at least 99% identity) with the disclosed polynucleotides.

The isolated polynucleotides of the present invention may also be usedas hybridization probes and primers to identify and isolate DNAs havingsequences encoding polypeptides homologous to the disclosedpolynucleotides. These homologs are polynucleotides and polypeptidesisolated from a different species than that of the disclosedpolypeptides and polynucleotides, or within the same species, but withsignificant sequence similarity to the disclosed polynucleotides andpolypeptides. Preferably, polynucleotide homologs have at least 50%sequence identity (more preferably, at least 75% identity; mostpreferably, at least 90% identity) with the disclosed polynucleotides,whereas polypeptide homologs have at least 30% sequence identity (morepreferably, at least 45% identity; most preferably, at least 60%identity) with the disclosed antibodies/polypeptides. Preferably,homologs of the disclosed polynucleotides and polypeptides are thoseisolated from mammalian species.

The isolated polynucleotides of the present invention may also be usedas hybridization probes and primers to identify cells and tissues thatexpress the antibodies of the present invention and the conditions underwhich they are expressed.

Additionally, the isolated polynucleotides of the present invention maybe used to alter (i.e., enhance, reduce, or modify) the expression ofthe genes corresponding to the polynucleotides of the present inventionin a cell or organism. These “corresponding genes” are the genomic DNAsequences of the present invention that are transcribed to produce themRNAs from which the polynucleotides of the present invention arederived.

The present invention also provides constructs in the form of plasmids,vectors, transcription or expression cassettes which comprise at leastone nucleic acid of the invention as above.

The isolated polynucleotides of the present invention may be operablylinked to an expression control sequence for recombinant production ofthe polypeptides of the present invention. Additionally one of skill inthe art will recognize that the polynucleotides of the invention may beoperably linked to well-known nucleotide sequences encoding the constantregion for various antibody isotypes. For example, a polynucleotide ofthe invention that encodes a light chain variable region(s) of theinvention (e.g., the sequence set forth in SEQ ID NOs:4 or 8) may beoperably linked to a nucleotide sequence that encodes the constantregion (or derivatives thereof) of either a κ light chain or λ lightchain, such that the expression of the linked nucleotides will result ina full kappa or lambda light chain with a variable region thatspecifically binds to and neutralizes GDF-8. Similarly, a polynucleotideof the invention that encodes a heavy chain variable region of theinvention (e.g., the sequence set forth in SEQ ID NOs:2 or 6) may beoperably linked to a nucleotide sequence that encodes the constantregion of a heavy chain isotype (or derivatives thereof), e.g., IgM,IgD, IgE, IgG and IgA. General methods of expressing recombinantproteins are well known in the art. Such recombinant proteins may beexpressed in soluble form for use in treatment of disorders related toGDF-8 activity, e.g., muscle and bone degenerative disorders.

The recombinant expression vectors of the invention may carry additionalsequences, such as sequences that regulate replication of the vector inhost cells (e.g., origins of replication), tag sequences such ashistidine, and selectable marker genes. The selectable marker genefacilitates selection of host cells into which the vector has beenintroduced. For example, typically the selectable marker gene confersresistance to drugs, such as G418, hygromycin or methotrexate, on a hostcell into which the vector has been introduced. Preferred selectablemarker genes include the dihydrofolate reductase (DHFR) gene (for use indhfr⁻ host cells with methotrexate selection/amplification) and the neogene (for G418 selection).

Suitable vectors, containing appropriate regulatory sequences, includingpromoter sequences, terminator sequences, polyadenylation sequences,enhancer sequences, marker genes and other sequences as appropriate, maybe either chosen or constructed. Vectors may be plasmids or viral, e.g.,phage, or phagemid, as appropriate. For further details see, forexample, Molecular Cloning: a Laboratory Manual: 2nd ed., Sambrook etal., Cold Spring Harbor Laboratory Press, 1989. Many known techniquesand protocols for manipulation of nucleic acid, for example, inpreparation of nucleic acid constructs, mutagenesis, sequencing,introduction of DNA into cells and gene expression, and analysis ofproteins, are described in detail in Current Protocols in MolecularBiology, 2nd ed., Ausubel et al. eds., John Wiley & Sons, 1992.

The present invention also provides a host cell that comprises one ormore constructs as above. A nucleic acid encoding any CDR (H1, H2, H3,L1, L2, or L3), VH or VL domain, or antigen-binding fragment as providedherein, forms an aspect of the present invention.

The present invention also includes a method of producing a peptide byexpressing the protein from the encoding nucleic acid in a host cell.Expression may be achieved by culturing recombinant host cellscontaining the nucleic acid under appropriate conditions.

Specific antibody fragments, VH and/or VL domains, and encoding nucleicacid molecules and vectors according to the present invention may beprovided isolated and purified, e.g., from their natural environment, insubstantially pure or homogeneous form, or, in the case of nucleicacids, free or substantially free of nucleic acids or genes of originother than the sequence encoding a polypeptide with the requiredfunction.

A number of cell lines are suitable host cells for recombinantexpression of the polypeptides and antibodies of the present invention.Mammalian host cell lines include, for example, COS cells, CHO cells,293T cells, A431 cells, 3T3 cells, CV-1 cells, HeLa cells, L cells,BHK21 cells, HL-60 cells, U937 cells, HaK cells, Jurkat cells, as wellas cell strains derived from in vitro culture of primary tissue andprimary explants. Such host cells also allow splicing of thepolynucleotides of the invention that consist of genomic DNA.

Alternatively, it may be possible to recombinantly produce thepolypeptides and antibodies of the present invention in lower eukaryotessuch as yeast or in prokaryotes. Potentially suitable yeast strainsinclude Saccharomyces cerevisiae, Schizosaccharomyces pombe,Kluyveromyces strains, and Candida strains. Potentially suitablebacterial strains include Escherichia coli, Bacillus subtilis, andSalmonella typhimurium. If the polypeptides of the present invention aremade in yeast or bacteria, it may be necessary to modify them by, forexample, phosphorylation or glycosylation of appropriate sites, in orderto obtain functional proteins. Such covalent attachments may beaccomplished using well-known chemical or enzymatic methods.

The polypeptides and antibodies of the present invention may also berecombinantly produced by operably linking the isolated polynucleotidesof the present invention to suitable control sequences in one or moreinsect expression vectors, such as baculovirus vectors, and employing aninsect cell expression system. Materials and methods for baculovirus/Sf9expression systems are commercially available in kit form (e.g., theMAXBAC® kit, Invitrogen, Carlsbad, Calif.).

Following recombinant expression in the appropriate host cells, thepolypeptides and antibodies of the present invention may be purifiedfrom culture medium or cell extracts using known purification processes,such as gel filtration and ion exchange chromatography. Purification mayalso include affinity chromatography with agents known to bind thepolypeptides and antibodies of the present invention. These purificationprocesses may also be used to purify the polypeptides and antibodies ofthe present invention from natural sources.

Alternatively, the polypeptides and antibodies of the present inventionmay be recombinantly expressed in a form that facilitates purification.For example, the polypeptides may be expressed as fusions with proteinssuch as maltose-binding protein (MBP), glutathione-S-transferase (GST),or thioredoxin (TRX). Kits for expression and purification of suchfusion proteins are commercially available from New England BioLabs(Beverly, Mass.), Pharmacia (Piscataway, N.J.), and Invitrogen,respectively. The polypeptides and antibodies of the present inventioncan also be tagged with a small epitope and subsequently identified orpurified using a specific antibody to the epitope. A preferred epitopeis the FLAG epitope, which is commercially available from Eastman Kodak(New Haven, Conn.).

The polypeptides and antibodies of the present invention may also beproduced by known conventional chemical synthesis. Methods forchemically synthesizing the polypeptides and antibodies of the presentinvention are well known to those skilled in the art. Such chemicallysynthetic polypeptides and antibodies may possess biological propertiesin common with the natural purified polypeptides and antibodies, andthus may be employed as biologically active or immunological substitutesfor the natural polypeptides and antibodies.

A further aspect of the present invention provides a host cellcomprising nucleic acids, polypeptides, vectors, or antibodies andfragments thereof as disclosed herein. A still further aspect provides amethod comprising introducing a nucleic acid of the invention into ahost cell. The introduction may employ any available technique. Foreukaryotic cells, suitable techniques may include calcium phosphatetransfection, DEAE-Dextran, electroporation, liposome-mediatedtransfection and transduction using a retrovirus or another virus, e.g.,vaccinia or, for insect cells, baculovirus. For bacterial cells,suitable techniques may include calcium chloride transformation,electroporation and infection using bacteriophage.

The introduction of nucleic acids may be followed by causing or allowingprotein production from the nucleic acid, e.g., by culturing the hostcells under conditions suitable for gene expression. Such conditions arewell known in the art.

III. Methods of Treating, Ameliorating, Preventing, and Inhibiting theProgress of Bone, Adipose, Glucose Metabolism, Insulin and MuscleDisorders

The involvement of GDF-8 in ALS, and the discovery of the novelantibodies of the invention, enables methods for treating, alleviating,and ameliorating GDF-8-associated disorders, e.g., muscle disorders,neuromuscular disorders, bone degenerative disorders, metabolic orinduced bone disorders, glucose metabolism disorders, adipose disorders,and insulin-related disorders. In addition, the antibodies allow fordiagnosing, prognosing and monitoring the progress of bone, muscle,adipose or insulin disorders by measuring the level of GDF-8 in abiological sample. In particular, the antibodies of the invention can beused to treat an individual with ALS or other muscle disorder, or in amethod of distinguishing whether a patient is suffering from ALS oranother muscle disorder.

The antibodies and other molecules of the present invention are usefulto prevent, diagnose, or treat various medical disorders in humans oranimals. The antibodies can be used to inhibit or reduce one or moreactivities associated with GDF-8. Most preferably, the antibodiesinhibit or reduce one or more of the activities of GDF-8 relative tounbound GDF-8 activities. In certain embodiments, the activity of GDF-8,when bound by one or more anti-GDF-8 antibody is inhibited at least 50%,preferably at least 60, 62, 64, 66, 68, 70, 72, 72, 76, 78, 80, 82, 84,86, or 88%, more preferably at least 90, 91, 92, 93, or 94%, and evenmore preferably at least 95% to 100% relative to a mature GDF-8 proteinthat is not bound by one or more of the anti-GDF-8 antibodies Inhibitionor neutralization of GDF-8 activity can be measured, e.g., inpGL3(CAGA)₁₂ reporter gene assays (RGA) as described in Thies et al.,supra, and in ActRIIB receptor assays as illustrated in the Examples.

The medical disorders diagnosed, prognosed, monitored, treated,ameliorated or prevented by GDF-8 antibodies are GDF-8-associateddisorders, e.g., muscle or neuromuscular disorders including, e.g.,muscular dystrophy (MD; including Duchenne's muscular dystrophy),amyotrophic lateral sclerosis (ALS), muscle atrophy, organ atrophy,frailty, carpal tunnel syndrome, congestive obstructive pulmonarydisease, sarcopenia, cachexia, and other muscle wasting syndromes (e.g.,caused by other diseases and conditions). In addition, other medicaldisorders that may be diagnosed, prognosed, monitored, treated,ameliorated or prevented by the GDF-8 antibodies are adipose tissuedisorders such as obesity, type 2 diabetes, impaired glucose tolerance,metabolic syndromes (e.g., syndrome X), insulin resistance induced bytrauma (such as burns or nitrogen imbalance), or bone degenerativediseases (e.g., osteoarthritis, osteoporosis, etc.). In preferredembodiments, the disorders that are diagnosed, prognosed, monitored,treated, ameliorated or prevented by GDF-8 antibodies are muscular orneuromuscular disorders. In a more preferred embodiment, the muscular orneuromuscular disorder that is diagnosed, prognosed, monitored, treated,ameliorated or prevented by anti-GDF-8 antibodies is either MD or ALS.In the most preferred embodiment of the invention, the muscular orneuromuscular disorder that is diagnosed, prognosed, monitored, treated,ameliorated or prevented by GDF-8 antagonists of the present invention,e.g., antibodies that inhibit GDF-8 activity, is ALS.

Other medical disorders that may be diagnosed, prognosed, monitored,treated, ameliorated or prevented by GDF-8 antagonists are thoseassociated with a loss of bone, which include osteoporosis, especiallyin the elderly and/or postmenopausal women, glucocorticoid-inducedosteoporosis, osteopenia, osteoarthritis, and osteoporosis-relatedfractures. Other target metabolic bone diseases and disorders includelow bone mass due to chronic glucocorticoid therapy, premature gonadalfailure, androgen suppression, vitamin D deficiency, secondaryhyperparathyroidism, nutritional deficiencies, and anorexia nervosa. Theantibodies are preferably used to diagnose, prognose, monitor, treat,ameliorate or prevent such disorders in mammals, particularly in humans.

The antibodies of the present invention are administered intherapeutically effective amounts. Generally, a therapeuticallyeffective amount may vary with the subject's age, condition, and sex, aswell as the severity of the medical condition in the subject. The dosagemay be determined by a physician and adjusted, as necessary, to suitobserved effects of the treatment. Toxicity and therapeutic efficacy ofsuch compounds can be determined by standard pharmaceutical proceduresin cell cultures or experimental animals, e.g., for determining the LD₅₀(the dose lethal to 50% of a population) and the ED₅₀ (the dosetherapeutically effective in 50% of a population). The dose ratiobetween toxic and therapeutic effects, i.e., the LD₅₀/ED₅₀, is thetherapeutic index, and antibodies exhibiting large therapeutic indicesare preferred.

The data obtained from cell culture assays and animal studies can beused in formulating a range of dosage for use in humans. The dosage ofsuch compounds lies preferably within a range of circulatingconcentrations that includes the ED₅₀ with little or no toxicity. Thedosage may vary within this range depending upon the form of dosage andthe route of administration. For any antibody used in the presentinvention, the therapeutically effective dose can be estimated initiallyfrom cell culture assays. A dose may be formulated in animal models toachieve a circulating plasma concentration range that includes the IC₅₀(e.g., the concentration of the test antibody which achieves ahalf-maximal inhibition of symptoms or half-maximal inhibition ofinhibition of biological activity) as determined in cell culture. Levelsin plasma may be measured, for example, by high performance liquidchromatography. The effects of any particular dosage can be monitored bya suitable bioassay. Examples of suitable bioassays include, but are notlimited to, DNA replication assays, transcription-based assays, GDF-8protein/receptor binding assays, creatine kinase assays, assays based onthe differentiation of preadipocytes, assays based on glucose uptake inadipocytes, and immunological assays.

Generally, the compositions are administered so that antibodies or theirbinding fragments are given at a dose from 1 μg/kg to 150 mg/kg, 1 μg/kgto 100 mg/kg, 1 μg/kg to 50 mg/kg, 1 μg/kg to 20 mg/kg, 1 μg/kg to 10mg/kg, 1 μg/kg to 1 mg/kg, 10 μg/kg to 1 mg/kg, 10 μg/kg to 100 μg/kg,100 μg to 1 mg/kg, and 500 μg/kg to 1 mg/kg. Preferably, the antibodiesare given as a bolus dose to maximize the circulating levels ofantibodies for the greatest length of time after the dose. Continuousinfusion may also be used before, after, or in place of the bolus dose.

IV. Methods of Identifying Therapeutic Agents

Yet another aspect of the invention provides a method of identifyingtherapeutic agents useful in treatment of muscle, e.g., glucosemetabolism, adipose, and bone disorders. Appropriate screening assays,e.g., ELISA-based assays, are known in the art. In such a screeningassay, a first binding mixture is formed by combining an antibody of theinvention and its ligand, GDF-8, and the amount of binding between theligand and the antibody in the first binding mixture (M₀) is measured. Asecond binding mixture is also formed by combining the antibody, theligand, and a compound or agent to be screened, and the amount ofbinding between the ligand and the antibody in the second bindingmixture (M₁) is measured. The amounts of binding in the first and secondbinding mixtures are then compared, for example, by calculating theM₁/M₀ ratio. The compound or agent is considered to be capable ofinhibiting GDF-8 activity if a decrease in binding in the second bindingmixture as compared to the first binding mixture is observed (i.e.,M₁/M₀<1). The formulation and optimization of binding mixtures is withinthe level of skill in the art; such binding mixtures may also containbuffers and salts necessary to enhance or to optimize binding, andadditional control assays may be included in the screening assay of theinvention.

Compounds found to reduce the antibody-ligand binding by at least about10% (i.e., M₁/M₀<0.9), preferably greater than about 30%, may thus beidentified and then, if desired, secondarily screened for the capacityto inhibit GDF-8 activity in other assays such as the ActRIIB bindingassay, or other cell-based and in vivo assays as described in theExamples or well known in the art.

V. Small Molecules

Inhibiting GDF-8 activity in an organism (or subject) afflicted with (orat risk for) a GDF-8-associated disorder, or in a cell from such anorganism involved in such disorders, may also be achieved through theuse of antagonist small molecules (usually organic small molecules) thatantagonize, i.e., inhibit the activity of, GDF-8. Novel antagonisticsmall molecules may be identified by the screening methods describedabove and may be used in the treatment methods of the present inventiondescribed herein.

Conversely, increasing GDF-8 activity in an organism (or subject)afflicted with (or at risk for) a disorder related to decreased GDF-8expression and/or activity or a disorder related to decreased GDF-8levels may also be achieved through the use of small molecules (usuallyorganic small molecules) that agonize, i.e., enhance the activity of,GDF-8. Novel agonistic small molecules may be identified by thescreening methods described above and may be used in the treatmentmethods of the present invention described herein.

VI. Methods of Diagnosing, Prognosing, and Monitoring the Progress ofBone, Adipose, Glucose Metabolism, and Muscle Disorders

In addition to treating, e.g., muscle, bone, glucose metabolism, andadipose disorders, the present invention provides methods for diagnosingsuch disorders by detecting the decrease or increase of GDF-8 in abiological sample, e.g., serum, plasma, bronchoalveolar lavage fluid,sputum, biopsies (e.g., of muscle), etc. “Diagnostic” or “diagnosing”means identifying the presence or absence of a pathologic condition.Diagnostic methods involve detecting the presence of GDF-8 by, e.g.,determining a test amount of GDF-8 polypeptide in a biological samplefrom a subject (human or nonhuman mammal), and comparing the test amountwith a normal amount or range (e.g., an amount or range from anindividual(s) known not to suffer from such a disorder) for the GDF-8polypeptide. While a particular diagnostic method may not provide adefinitive diagnosis of ALS or other GDF-8-associated disorders, itsuffices if the method provides a positive indication that aids indiagnosis.

The present invention also provides methods for prognosing ALS or othermuscle disorders, or e.g., bone, glucose metabolism, and adiposedisorders by detecting upregulation of GDF-8. “Prognostic” or“prognosing” means predicting the probable development and/or severityof a pathologic condition. Prognostic methods involve determining thetest amount of GDF-8 in a biological sample from a subject, andcomparing the test amount to a prognostic amount or range (e.g., anamount or range from individuals with varying severities of, e.g., ALS)for GDF-8. Various amounts of the GDF-8 in a test sample are consistentwith certain prognoses for ALS or other GDF-8-associated disorders. Thedetection of an amount of GDF-8 at a particular prognostic levelprovides a prognosis for the subject.

The present invention also provides methods for monitoring the course ofALS or other GDF-8-associated disorders by detecting the upregulation ordownregulation of GDF-8. Monitoring methods involve determining the testamounts of GDF-8 in biological samples taken from a subject at a firstand second time, and comparing the amounts. A change in amount of GDF-8between the first and second time indicates a change in the course of,e.g., severity of, ALS or other GDF-8-associated disorders. A skilledartisan will recognize that in GDF-8-associated disorders similar toALS, e.g., where an increase in muscle mass is desirable, a decrease inamount of GDF-8 and/or GDF-8 activity between the first and second timeindicates remission of the disorder, and an increase in amount indicatesprogression of the disorder. Such monitoring assays are also useful forevaluating the efficacy of a particular therapeutic intervention (e.g.,disease attenuation and/or reversal) in patients being treated for ALSor other GDF-8-associated disorders.

The antibodies of the present invention may be used for diagnosis,prognosis or monitoring by detecting the presence of GDF-8 in vivo or invitro. Such detection methods are well known in the art and includeELISA, radioimmunoassay, immunoblot, Western blot, immunofluorescence,immunoprecipitation, and other comparable techniques. The antibodies mayfurther be provided in a diagnostic kit that incorporates one or more ofthese techniques to detect GDF-8. Such a kit may contain othercomponents, packaging, instructions, or other material to aid thedetection of the protein and use of the kit.

Where the antibodies are intended for diagnostic, prognostic, ormonitoring purposes, it may be desirable to modify them, for example,with a ligand group (such as biotin) or a detectable marker group (suchas a fluorescent group, a radioisotope or an enzyme). If desired, theantibodies (whether polyclonal or monoclonal) may be labeled usingconventional techniques. Suitable labels include fluorophores,chromophores, radioactive atoms, electron-dense reagents, enzymes, andligands having specific binding partners. Enzymes are typically detectedby their activity. For example, horseradish peroxidase can be detectedby its ability to convert tetramethylbenzidine (TMB) to a blue pigment,quantifiable with a spectrophotometer. Other suitable labels may includebiotin and avidin or streptavidin, IgG and protein A, and the numerousreceptor-ligand couples known in the art. Other permutations andpossibilities will be readily apparent to those of ordinary skill in theart, and are considered as equivalents within the scope of the instantinvention.

VII. Pharmaceutical Compositions and Methods of Administration

The present invention provides compositions comprising a GDF-8antagonist of the invention, i.e., polypeptides, polynucleotides,vectors, antibodies, antibody fragments, and small molecules. Suchcompositions may be suitable for pharmaceutical use and administrationto patients. The compositions typically comprise one or more moleculesof the present invention, preferably an antibody, and a pharmaceuticallyacceptable excipient. The anti-GDF-8 antibodies of the present inventioncan be used in vitro, ex vivo, or incorporated into a pharmaceuticalcomposition when combined with a pharmaceutically acceptable carrier. Asused herein, the phrase “pharmaceutically acceptable excipient” includesany and all solvents, solutions, buffers, dispersion medias, coatings,antibacterial and antifungal agents, isotonic and absorption delayingagents, and the like, that are compatible with pharmaceuticaladministration. Such a composition may contain, in addition to theantibodies of the invention and carrier, various diluents, fillers,salts, buffers, stabilizers, solubilizers, and other materials wellknown in the art. The term “pharmaceutically acceptable” means anontoxic material that does not interfere with the effectiveness of thebiological activity of the active ingredient(s). The characteristics ofthe carrier will depend on the route of administration. The use of suchmedia and agents for pharmaceutically active substances is well known inthe art. The compositions may also contain other active compoundsproviding supplemental, additional, or enhanced therapeutic functions.The pharmaceutical compositions may also be included in a container,pack, or dispenser together with instructions for administration.

The pharmaceutical composition of the invention may be in the form of aliposome in which an antibody of the invention is combined, in additionto other pharmaceutically acceptable carriers, with amphipathic agentssuch as lipids that exist in aggregated form as micelles, insolublemonolayers, liquid crystals, or lamellar layers while in aqueoussolution. Suitable lipids for liposomal formulation include, withoutlimitation, monoglycerides, diglycerides, sulfatides, lysolecithin,phospholipids, saponin, bile acids, and the like. Preparation of suchliposomal formulations is within the level of skill in the art.

As used herein, the term “therapeutically effective amount” means thetotal amount of each active component of the pharmaceutical compositionor method that is sufficient to show a meaningful patient benefit, e.g.,amelioration of symptoms of, healing of, or increase in rate of healingof such conditions. When applied to an individual active ingredient,administered alone, the term refers to that ingredient alone. Whenapplied to a combination, the term refers to combined amounts of theactive ingredients that result in the therapeutic effect, whetheradministered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, atherapeutically effective amount of, e.g., an antibody that binds toGDF-8 and interferes with GDF-8 signaling is administered to a subject,e.g., mammal (e.g., a human). An antibody of the invention may beadministered in accordance with the method of the invention either aloneor in combination with other therapies such as anti-inflammatory agents.When coadministered with one or more agents, an antibody of theinvention may be administered either simultaneously with the secondagent, or sequentially. If administered sequentially, the attendingphysician will decide on the appropriate sequence of administering anantibody of the invention in combination with other agents.

In one embodiment, the antibodies of the invention, e.g., pharmaceuticalcompositions thereof, are administered in combination therapy, i.e.,combined with other agents, e.g., therapeutic agents, that are usefulfor treating pathological conditions or disorders, such as muscledisorders, neuromuscular disorders, bone degenerative disorders,metabolic or induced bone disorders, adipose disorders, glucosemetabolism disorders or insulin-related disorders, e.g., as well asallergic and inflammatory disorders. The term “in combination” in thiscontext means that the agents are given substantially contemporaneously,either simultaneously or sequentially. If given sequentially, at theonset of administration of the second compound, the first of the twocompounds is preferably still detectable at effective concentrations atthe site of treatment or in the subject.

A pharmaceutical composition of the invention is formulated to becompatible with its intended route of administration. Methods toaccomplish the administration are known to those of ordinary skill inthe art. It may also be possible to obtain compositions which may betopically or orally administered, or which may be capable oftransmission across mucous membranes. Administration of an antibody ofthe invention used in a pharmaceutical composition to practice themethod of the present invention can be carried out in a variety ofconventional ways, such as oral ingestion, inhalation, cutaneous,subcutaneous, or intravenous injection.

Solutions or suspensions used for intradermal or subcutaneousapplication typically include one or more of the following components: asterile diluent such as water for injection, saline solution, fixedoils, polyethylene glycols, glycerine, propylene glycol or othersynthetic solvents; antibacterial agents such as benzyl alcohol ormethyl parabens; antioxidants such as ascorbic acid or sodium bisulfite;chelating agents such as ethylenediaminetetraacetic acid; buffers suchas acetates, citrates or phosphates; and agents for the adjustment oftonicity such as sodium chloride or dextrose. The pH can be adjustedwith acids or bases, such as hydrochloric acid or sodium hydroxide. Suchpreparations may be enclosed in ampoules, disposable syringes ormultiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injection include sterileaqueous solutions or dispersions and sterile powders for theextemporaneous preparation of sterile injectable solutions ordispersion. For intravenous administration, suitable carriers includephysiological saline, bacteriostatic water, CREMOPHOR™ EL (BASF,Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, thecomposition must be sterile and should be fluid to the extent that easysyringability exists. It must be stable under the conditions ofmanufacture and storage and must be preserved against the contaminatingaction of microorganisms such as bacteria and fungi. The carrier can bea solvent or dispersion medium containing, for example, water, ethanol,polyol (for example, glycerol, propylene glycol, and liquid polyethyleneglycol, and the like), and suitable mixtures thereof. The properfluidity can be maintained, for example, by the use of a coating such aslecithin, by the maintenance of the required particle size in the caseof dispersion and by the use of surfactants. Prevention of the action ofmicroorganisms can be achieved by various antibacterial and antifungalagents, for example, parabens, chlorobutanol, phenol, ascorbic acid,thimerosal, and the like. In many cases, it will be preferable toinclude isotonic agents, for example, sugars, polyalcohols such asmannitol, sorbitol, and sodium chloride in the composition. Prolongedabsorption of the injectable compositions can be brought about byincluding in the composition an agent which delays absorption, forexample, aluminum monostearate and gelatin.

When a therapeutically effective amount of an antibody of the inventionis administered by, e.g., intravenous, cutaneous or subcutaneousinjection, the binding agent will be in the form of a pyrogen-free,parenterally acceptable aqueous solution. The preparation of suchparenterally acceptable protein solutions, having due regard to pH,isotonicity, stability, and the like, is within the skill in the art. Apreferred pharmaceutical composition for intravenous, cutaneous, orsubcutaneous injection should contain, in addition to binding agents, anisotonic vehicle such as sodium chloride injection, Ringer's injection,dextrose injection, dextrose and sodium chloride injection, lactatedRinger's injection, or other vehicle as known in the art. Thepharmaceutical composition(s) of the present invention may also containstabilizers, preservatives, buffers, antioxidants, or other additiveknown to those of skill in the art.

The amount of an antibody of the invention (or other antagonist of theinvention) in the pharmaceutical composition of the present inventionwill depend upon the nature and severity of the condition being treated,and on the nature of prior treatments undergone by the patient.Ultimately, the attending physician will decide the amount of antibodywith which to treat each individual patient. Initially, an attendingphysician administers low doses of antibody and observes the patient'sresponse. Larger doses of antibody may be administered until the optimaltherapeutic effect is obtained for the patient, and at that point thedosage is generally not increased further. It is contemplated that thevarious pharmaceutical compositions used to practice the method of thepresent invention should contain about 0.1 μg to 50 mg antibody per kgbody weight.

The duration of therapy using the pharmaceutical composition of thepresent invention will vary, depending on the severity of the diseasebeing treated and the condition and potential idiosyncratic response ofeach individual patient. It is contemplated that the duration of eachapplication of antibody will be via, e.g., the subcutaneous route and,e.g., in the range of once a week. Ultimately the attending physicianwill decide on the appropriate duration of therapy using thepharmaceutical composition of the present invention.

Oral compositions generally include an inert diluent or an ediblecarrier. They can be enclosed in gelatin capsules or compressed intotablets. For the purpose of oral therapeutic administration, the GDF-8antagonist (e.g., antibody, small molecule, etc.) can be incorporatedwith excipients and used in the form of tablets or capsules.Pharmaceutically compatible binding agents, and/or adjuvant materialscan be included as part of the composition. The tablets, pills,capsules, and the like can contain any of the following ingredients, orcompounds of a similar nature; a binder such as microcrystallinecellulose, gum tragacanth or gelatin; an excipient such as starch orlactose; a disintegrating agent such as alginic acid, PRIMOGEL™, or cornstarch; a lubricant such as magnesium stearate or STEROTES™, a glidantsuch as colloidal silicon dioxide; a sweetening agent such as sucrose orsaccharin; or a flavoring agent such as peppermint, methyl salicylate,or orange flavoring.

When a therapeutically effective amount of a pharmaceutical compositionof the invention, e.g., an antibody that binds to GDF-8 and interfereswith GDF-8 signaling, is administered orally, the binding agent will bein the form of a tablet, capsule, powder, solution or elixir. Whenadministered in tablet form, the pharmaceutical composition of theinvention may additionally contain a solid carrier such as a gelatin oran adjuvant. The tablet, capsule, and powder contain from about 5 to 95%binding agent, and preferably from about 25 to 90% binding agent. Whenadministered in liquid form, a liquid carrier such as water, petroleum,oils of animal or plant origin such as peanut oil, mineral oil, soybeanoil, or sesame oil, or synthetic oils may be added (after taking intoaccount the allergies of the individual patient and/or vast populationof individuals to such liquid carriers). The liquid form of thepharmaceutical composition may further contain physiological salinesolution, dextrose or other saccharide solution, or glycols such asethylene glycol, propylene glycol or polyethylene glycol. Whenadministered in liquid form, the pharmaceutical composition containsfrom about 0.5 to 90% by weight of the binding agent, and preferablyfrom about 1 to 50% the binding agent.

For administration by inhalation, a GDF-8 antagonist is delivered in theform of an aerosol spray from a pressured container or dispenser, whichcontains a suitable propellant, e.g., a gas such as carbon dioxide, or anebulizer. Accordingly, the compounds described herein can beadministered by inhalation to pulmonary tissue. The term “pulmonarytissue” as used herein refers to any tissue of the respiratory tract andincludes both the upper and lower respiratory tract, except whereotherwise indicated. One or more GDF-8 antibodies can be administered incombination with one or more of the existing modalities for treatingpulmonary diseases.

In one example, the compound is formulated for a nebulizer. In oneembodiment, the compound can be stored in a lyophilized form (e.g., atroom temperature) and reconstituted in solution prior to inhalation.

It is also possible to formulate the compound for inhalation using amedical device, e.g., an inhaler (see, e.g., U.S. Pat. No. 6,102,035 (apowder inhaler) and U.S. Pat. No. 6,012,454 (a dry powder inhaler)). Theinhaler can include separate compartments for the active compound at apH suitable for storage and another compartment for a neutralizingbuffer, and a mechanism for combining the compound with a neutralizingbuffer immediately prior to atomization. In one embodiment, the inhaleris a metered dose inhaler.

Although not necessary, delivery enhancers such as surfactants can beused to further enhance pulmonary delivery. A “surfactant” as usedherein refers to a compound having hydrophilic and lipophilic moietiesthat promote absorption of a drug by interacting with an interfacebetween two immiscible phases. Surfactants are useful with dry particlesfor several reasons, e.g., reduction of particle agglomeration,reduction of macrophage phagocytosis, etc. When coupled with lungsurfactant, a more efficient absorption of the compound can be achievedbecause surfactants, such as DPPC, will greatly facilitate diffusion ofthe compound. Surfactants are well known in the art and include, but arenot limited to, phosphoglycerides, e.g., phosphatidylcholines,L-alpha-phosphatidylcholine dipalmitoyl (DPPC) and diphosphatidylglycerol (DPPG); hexadecanol; fatty acids; polyethylene glycol (PEG);polyoxyethylene-9-; auryl ether; palmitic acid; oleic acid; sorbitantrioleate (Span 85); glycocholate; surfactin; poloxomer; sorbitan fattyacid ester; sorbitan trioleate; tyloxapol; and phospholipids.

Systemic administration can also be by transmucosal or transdermalmeans. For example, in the case of antibodies that comprise the Fcportion, compositions may be capable of transmission across mucousmembranes (e.g., intestine, mouth, or lungs) via the FcRnreceptor-mediated pathway (e.g., U.S. Pat. No. 6,030,613). In general,transmucosal administration can be accomplished, for example, throughthe use of lozenges, nasal sprays, inhalers, or suppositories. Fortransdermal administration, the active compounds are formulated intoointments, salves, gels, patches or creams as generally known in theart. For transmucosal or transdermal administration, penetrantsappropriate to the barrier to be permeated are used in the formulation.Such penetrants are generally known in the art, and include, forexample, detergents, bile salts, and fusidic acid derivatives.

Pharmaceutical compositions may also consist of compositions suitablefor gene therapy, i.e., compositions comprised of the polynucleotidesdisclosed herein. In the case of gene therapy, the pharmaceuticallyacceptable carrier may include, e.g., lipids, collagen spheres, cationicemulsion systems, water, saline buffers, viral vectors, chylomicronremnants, polymer nanoparticles (e.g., gelatin-DNA or chitosan-DNA),gold particles, polymer complexes, lipoplexes, polyplexes, etc. (see,e.g., Gardlik et al. (2005) Med. Sci. Monit. 11(4):RA110-21).

Stabilization and Retention

In one embodiment, a GDF-8 antibody is physically associated with amoiety that improves its stabilization and/or retention in circulation,e.g., in blood, serum, lymph, bronchopulmonary or bronchoalveolarlavage, or other tissues, e.g., by at least 1.5, 2, 5, 10, or 50 fold.

The antagonists of the invention may be prepared with carriers that willprotect against rapid elimination from the body, such as acontrolled-release formulation, including implants and microencapsulateddelivery systems. Biodegradable, biocompatible polymers can be used,such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid,collagen, polyorthoesters, and polylactic acid. Methods for preparationof such formulations will be apparent to those skilled in the art.Liposomal suspensions containing a GDF-8 antagonist, e.g., one or moreanti-GDF-8 antibodies, can also be used as pharmaceutically acceptablecarriers. These can be prepared according to methods known to thoseskilled in the art.

For example, a GDF-8 antibody can be associated with a polymer, e.g., asubstantially nonantigenic polymer, such as polyalkylene oxides orpolyethylene oxides. Suitable polymers will vary substantially byweight. Polymers having molecular number average weights ranging fromabout 200 to about 35,000 (or about 1,000 to about 15,000, or about2,000 to about 12,500) can be used.

For example, a GDF-8 antibody can be conjugated to a water-solublepolymer, e.g., hydrophilic polyvinyl polymers, e.g., polyvinylalcoholand polyvinylpyrrolidone. A nonlimiting list of such polymers includepolyalkylene oxide homopolymers such as polyethylene glycol (PEG) orpolypropylene glycols, polyoxyethylenated polyols, copolymers thereofand block copolymers thereof, provided that the water solubility of theblock copolymers is maintained. Additional useful polymers includepolyoxyalkylenes such as polyoxyethylene, polyoxypropylene, and blockcopolymers of polyoxyethylene and polyoxypropylene (Pluronics);polymethacrylates; carbomers; branched or unbranched polysaccharides,which comprise the saccharide monomers D-mannose, D- and L-galactose,fucose, fructose, D-xylose, L-arabinose, D-glucuronic acid, sialic acid,D-galacturonic acid, D-mannuronic acid (e.g., polymannuronic acid, oralginic acid), D-glucosamine, D-galactosamine, D-glucose and neuraminicacid including homopolysaccharides and heteropolysaccharides such aslactose, amylopectin, starch, hydroxyethyl starch, amylose, dextranesulfate, dextran, dextrins, glycogen, or the polysaccharide subunit ofacid mucopolysaccharides, e.g., hyaluronic acid; polymers of sugaralcohols such as polysorbitol and polymannitol; heparin, etc.

Other compounds can also be attached to the same polymer, e.g., acytotoxin, a label, or another targeting agent, e.g., another GDF-8antibody or an unrelated ligand. Mono-activated, alkoxy-terminatedpolyalkylene oxides (PAOs), e.g., monomethoxy-terminated polyethyleneglycols (mPEGs), C₁₋₄ alkyl-terminated polymers, and bis-activatedpolyethylene oxides (glycols) can be used for cross-linking (see, e.g.,U.S. Pat. No. 5,951,974).

In one embodiment, the polymer prior to cross-linking to the ligand neednot be, but preferably is, water-soluble. Generally, aftercross-linking, the product is water-soluble, e.g., exhibits a watersolubility of at least about 0.01 mg/ml, and more preferably at leastabout 0.1 mg/ml, and still more preferably at least about 1 mg/ml. Inaddition, the polymer should not be highly immunogenic in the conjugateform, nor should it possess viscosity that is incompatible withintravenous infusion, aerosolization, or injection, if the conjugate isintended to be administered by such routes.

In one embodiment, the polymer contains only a single group that isreactive. This helps to avoid cross-linking of ligand molecules to oneanother. However, it is within the scope herein to maximize reactionconditions to reduce cross-linking between ligand molecules, or topurify the reaction products through gel filtration or ion exchangechromatography to recover substantially homogenous derivatives. In otherembodiments, the polymer contains two or more reactive groups for thepurpose of linking multiple ligands to the polymer backbone. Again, gelfiltration or ion exchange chromatography can be used to recover thedesired derivative in substantially homogeneous form.

The molecular weight of the polymer can range up to about 500,000 D, andpreferably is at least about 20,000 D, or at least about 30,000 D, or atleast about 40,000 D. The molecular weight chosen can depend upon theeffective size of the conjugate to be achieved, the nature (e.g.,structure, such as linear or branched) of the polymer, and the degree ofderivatization.

A covalent bond can be used to attach a GDF-8 antibody to a polymer, forexample, cross-linking to the N-terminal amino group of the ligand andepsilon amino groups found on lysine residues of the ligand, as well asother amino, imino, carboxyl, sulfhydryl, hydroxyl or other hydrophilicgroups. The polymer may be covalently bonded directly to the GDF-8antibody without the use of a multifunctional (ordinarily Afunctional)cross-linking agent. Covalent binding to amino groups is accomplished byknown chemistries based upon cyanuric chloride, carbonyl diimidazole,aldehyde-reactive groups (PEG alkoxide plus diethyl acetyl ofbromoacetaldehyde; PEG plus DMSO and acetic anhydride, or PEG chlorideplus the phenoxide of 4-hydroxybenzaldehyde, activated succinimidylesters, activated dithiocarbonate PEG, 2,4,5-trichlorophenylcloroformateor P-nitrophenylchloroformate activated PEG.) Carboxyl groups can bederivatized by coupling PEG-amine using carbodiimide. Sulfhydryl groupscan be derivatized by coupling to maleimido-substituted PEG (e.g.,alkoxy-PEG amine plus sulfosuccinimidyl4-(N-maleimidomethyl)cyclohexane-1-carboxylate) (see WO 97/10847) orPEG-maleimide). Alternatively, free amino groups on the ligand (e.g.,epsilon amino groups on lysine residues) can be thiolated with2-imino-thiolane (Traut's reagent) and then coupled tomaleimide-containing derivatives of PEG, e.g., as described in Pedley etal. (1994) Br. J. Cancer 70:1126-30.

Functionalized PEG polymers that can be attached to a GDF-8 antibody areavailable, e.g., from Shearwater Polymers, Inc. (Huntsville, Ala.). Suchcommercially available PEG derivatives include, e.g., amino-PEG, PEGamino acid esters, PEG-hydrazide, PEG-thiol, PEG-succinate,carboxymethylated PEG, PEG-propionic acid, PEG amino acids, PEGsuccinimidyl succinate, PEG succinimidyl propionate, succinimidyl esterof carboxymethylated PEG, succinimidyl carbonate of PEG, succinimidylesters of amino acid PEGs, PEG-oxycarbonylimidazole, PEG-nitrophenylcarbonate, PEG tresylate, PEG-glycidyl ether, PEG-aldehyde, PEGvinylsulfone, PEG-maleimide, PEG-orthopyridyl-disulfide,heterofunctional PEGs, PEG vinyl derivatives, PEG silanes, and PEGphospholides. The reaction conditions for coupling these PEG derivativesmay vary depending on the GDF-8 antibody, the desired degree ofPEGylation, and the PEG derivative utilized. Some factors involved inthe choice of PEG derivatives include: the desired point of attachment(such as lysine or cysteine R-groups), hydrolytic stability andreactivity of the derivatives, stability, toxicity and antigenicity ofthe linkage, suitability for analysis, etc. Specific instructions forthe use of any particular derivative are available from themanufacturer.

The conjugates of a GDF-8 antibody and a polymer can be separated fromthe unreacted starting materials, e.g., by gel filtration or ionexchange chromatography, or other forms of chromatography, e.g., HPLC.Heterologous species of the conjugates are purified from one another inthe same fashion. Resolution of different species (e.g., containing oneor two PEG residues) is also possible due to the difference in the ionicproperties of the unreacted amino acids (see, e.g., WO 96/34015).

The polynucleotides and proteins of the present invention are expectedto exhibit one or more of the uses or biological activities (includingthose associated with assays cited below) identified herein. Uses oractivities described for proteins of the present invention may beprovided by administration or use of such proteins, or by administrationor use of polynucleotides encoding such proteins (such as, e.g., in genetherapies or vectors suitable for introduction of DNA).

It may be advantageous to formulate oral or parenteral compositions indosage unit form for ease of administration and uniformity of dosage.Dosage unit form as used herein refers to physically discrete unitssuited as unitary dosages for the subject to be treated, each unitcontaining a predetermined quantity of active compound calculated toproduce the desired therapeutic effect in association with the requiredpharmaceutical carrier. The specification for the dosage unit forms ofthe invention are dictated by and directly dependent on the uniquecharacteristics of the active compound, the particular therapeuticeffect to be achieved, and the limitations inherent in the art offormulating such an active compound for the treatment of individuals.

Another aspect of the present invention accordingly relates to kits forcarrying out the administration of the GDF-8 antibodies of theinvention, e.g., with or without other therapeutic compounds, or forusing the anti-GDF-8 antibodies as a research or therapeutic tool todetermine the presence and/or level of GDF-8 in a biological sample,such as an ELISA kit. In one embodiment, the kit comprises one or moreanti-GDF-8 antibodies formulated in a pharmaceutical carrier, and atleast one agent, e.g., a therapeutic agent, formulated as appropriate,in one or more separate pharmaceutical preparations.

The Examples which follow are set forth to aid in the understanding ofthe invention but are not intended to, and should not be construed to,limit the scope of the invention in any way. The Examples do not includedetailed descriptions of conventional methods, such as hybridomaformation, ELISA, proliferation assays, flow cytometric analysis andrecombinant DNA techniques. Such methods are well known to those ofordinary skill in the art.

The entire contents of all references, patents, published patentapplications, and other patent documents cited throughout thisapplication are hereby incorporated by reference herein.

EXAMPLES Example 1 Creation and Identification of Anti-GDF-8 AntibodyRK35

Human GDF-8 protein (mature GDF-8 and GDF-8 propeptide) and BMP-11protein were isolated and characterized as described in U.S. PublishedPatent Application No. 2004/0142382.

Six female myostatin knockout BALB/c mice (8 weeks old; McPherron etal., supra) were immunized by subcutaneous injections with 20 μg ofrecombinant GDF-8 dimer in Freund's complete adjuvant.

Several booster injections of the same amount of antigen in Freund'sincomplete adjuvant were given at 2-week intervals and a finalintravenous injection (tail vein) of 2 μg in PBS was given prior to thefusion. Splenocytes from two of the mice demonstrating the highestantibody titers were fused with mouse myeloma cells (ATCC Accession No.P3X63.Ag8.653) using standard techniques (Oi and Herzenberger (1980) In:Mishell, B. B., Shiigi, S. M., Henry, C., Mishell, R. I. (Eds.),Selected Methods in Cellular Immunology W.H. Freemen, San Francisco, pp.351-72). After 10-14 days, the supernatants were harvested and screenedfor anti-GDF-8 antibody production by solid and solution phase ELISA(Whittemore et al., supra). Standard ELISA techniques and thepGL3-(CAGA)₁₂ reporter assay (Theis et al (2001) Growth Factors18:251-59) were used to determine the IC₅₀ for inhibition of binding ofmyostatin to its receptor, ActRIIB, using a chimeric ActRIIB-Fcgenerated by fusing the extracellular domain of the human ActRIIB-Fcreceptor with human IgG1 Fc region. Hybridomas chosen for furtherstudies were rendered monoclonals by repeated limiting dilution toensure monoclonality. Monoclonal antibody RK35 was selected for furtherstudy.

Example 2 RK35 Monoclonal Antibody has High Affinity for GDF-8 andExhibits Neutralization Activity Example 2.1: Experimental Procedures

For the ELISA, biotinylated GDF-8 was coated overnight at 4° C. onto96-well streptavidin microtiter plates (Pierce, Rockford, Ill.) at 1μg/ml. After coating, the solutions were removed from the wells, and theplates blocked for 1 hour at room temperature in SuperBlock solution(Pierce). Plates were rinsed with PBS, and 100 μl of RK35 antibody wasadded to the wells at various concentrations. The plates were incubatedat room temperature for 1 hour and then washed with PBS. To each well,100 μl of a 1:5000 dilution of anti-huIgG-HRP conjugate (SouthernBiotech, Birmingham, Ala.) was added and the plates were incubated atroom temperature for 1 hour. Each plate was washed three times with PBS.TMB substrate (100 μl) was added to each well and incubated until colordevelopment. The reaction was stopped by the addition of 100 μl of 0.18M H₂SO₄. The signal generated was measured by reading the absorbance at450 nm using a microtiter plate reader. Binding to GDF-8 was confirmedusing human isotype control antibody.

Recombinant ActRIIB-Fc chimera (R&D Systems, Minneapolis, Minn., Cat.No. 339-RB/CF) was coated on 96-well flat-bottom assay plates (Costar,N.Y., Cat. No. 3590) at 1 μg/ml in 0.2 M sodium carbonate bufferovernight at 4° C. Plates were then blocked with 1 mg/ml bovine serumalbumin and washed following standard ELISA protocol. Aliquots (100 μl)of biotinylated GDF-8 or BMP-11 were added to the blocked ELISA plate atvarious concentrations, incubated for 1 hr, washed, and the amount ofbound GDF-8 or BMP-11 was detected by streptavidin-horseradishperoxidase (SA-HRP, BD PharMingen, San Diego, Calif., Cat. No. 13047E)followed by the addition of TMB (KPL, Gaithersburg, Md., Cat. No.50-76-04). Colorimetric measurements were taken at 450 nm in a MolecularDevices microplate reader. To analyze the inhibitory activity, RK35 wastested at various concentrations by preincubation with 20 ng/ml GDF-8 or20 ng/ml BMP-11. After incubation for 1 hr at room temperature, 100 μlof RK35 and GDF-8 or BMP-11 mixture was added to the plate. Detectionand quantitation of bound factor is described in Whittemore et al.(2003) Biochem. Biophys. Res. Commun. 300:965-71.

To demonstrate the activity of GDF-8, a reporter gene assay (RGA) wasdeveloped using a reporter vector pGL3(CAGA)₁₂ expressing luciferaseunder control of TGF-β induced promoter. The CAGA is a TGF-β-responsivesequence within the promoter of the TGF-β-induced gene PAI-1 (Denner etal. (1998) EMBO J. 17:3091-3100). A reporter vector containing 12 CAGAboxes was made using the basic luciferase reporter plasmid pGL3(Promega, Madison, Wis.). The TATA box and transcription initiation sitefrom the adenovirus major later promoter (−35/+10) was inserted betweenthe BglII and HindIII sites. Oligonucleotides containing 12 repeats ofthe CAGA boxes, i.e., AGCCAGACA, were annealed and cloned into the Xholsite. The human rhabdomyosarcoma cell line A204 (ATCC HTB-82) wastransiently transfected with pGL3(CAGA)₁₂ using FuGENE 6 transfectionreagent (Boehringer Manheim, Germany). Following transfection, cellswere cultured on 96-well plates in McCoy's 5A medium supplemented with 2mM glutamine, 100 U/ml streptomycin, 100 μg/ml penicillin and 10% fetalcalf serum for 16 hrs. Cells were then treated with or without 10 ng/mlGDF-8 in McCoy's 5A medium with glutamine, streptomycin, penicillin, and1 mg/ml bovine serum albumin for 6 hrs at 37° C. Luciferase wasquantified in the treated cells using the Luciferase Assay System(Promega). To test the inhibitory activity of RK35, GDF-8 waspreincubated with the antibody for 1 hr at room temperature. Thismixture was then added to the transfected cells and cells were incubatedfor 6 hrs at 37° C. Luciferase was quantified using the Luciferase AssaySystem (Promega).

Example 2.2: Results

A high affinity mouse monoclonal antibody to myostatin was generated byimmunizing GDF-8 knockout mice with purified recombinant human GDF-8,which is identical in amino acid sequence to mature murine myostatin(McPherron et al., 1997). The RK35 antibody bound with high affinity toGDF-8 as tested by direct ELISA (4 nM; FIG. 1A). A competition ELISA wasused to assess the ability of RK35 to inhibit GDF-8 binding to its highaffinity receptor, ActRIIB RK35 blocked binding of biotinylated GDF-8 toimmobilized ActRIIB-Fc with an IC50˜2.5 nM (FIG. 1B). Soluble ActRIIbalso blocked binding of GDF-8 to immobilized ActRIIb-Fc while controlantibodies did not block binding. The neutralization activity of RK35was also measured using a pGL3-(CAGA)12 cell based reporter assay. Inthis assay the luciferase gene was cloned under control of GDF-8/TGF-βresponsive promoter and human A204 rhabdomyosarcoma cells weretransiently transfected with the reporter plasmid. Increases inluciferase activity in A204 cells induced by GDF-8 were blocked in adose dependent manner by RK35 (FIG. 1C). RK35 reduced the GDF-8 signaltransduction activity with an IC50 of 0.2 nM. Therefore, RK35 is a newhighly potent murine monoclonal neutralizing antibody directed againstGDF-8.

Example 3 In Vivo Activity of RK35 in Wild Type and ALS Rodent ModelsExample 3.1: Experimental Procedures Example 3.1.1: Animals and DrugTreatment

All procedures involving animals were approved by the IACUC of eitherthe University of Pennsylvania or Wyeth. Transgenic mice expressinghuman SODG93A (Gurney et al., supra) on a B6SJL hybrid background(Jackson Laboratories) were mated in-house to B6SJLF1 female breedermice (Jackson Laboratories). Progeny were screened by PCR; mice negativefor the transgene were used as aged-matched littermate wild typecontrols. Mice were divided into four groups: 29 SODG93A mice treatedwith the anti-myostatin antibody RK35, 28 SODG93A mice treated withphosphate-buffered saline (PBS) (vehicle), 23 wild type mice treatedwith RK35, and 23 wild type mice treated with PBS. Starting at 28 daysafter birth, mice were intraperitoneally injected on a weekly basis,with either anti-GDF-8 monoclonal antibody RK35 or an equivalent volumeof PBS. The first dose was 40 mg/kg; subsequent doses were 20 mg/kg/weekfollowing the protocol described by for the anti-myo statin antibodyJA16 (Whittemore, et al., supra). 9-12 mice from each group weresacrificed between 84 and 90 days (12 weeks) in age (mean of 88 days) toassess wet muscle mass and histology, and the remaining mice weremonitored until reaching end-stage disease (−134 days), defined as afailure to right within 30 sec from both left and right lateralrecumbency.

In parallel, transgenic rats (58) expressing human SODG93A (Howland etal., supra) in an equal mix of males and females were administeredeither PBS (vehicle) or RK35. Ten rats in each group were euthanized at95 days in age to determine the effect of RK35 on wet muscle mass. Theremaining 19 rats in each group continued through to end-stage disease.A second study using female transgenic and wild type littermate controlrats was used to compare body weight increases as well as grip strengthchanges across treatment groups and genotype. In each study, rats wereintraperitoneally injected with RK35 at 40 mg/kg (at 6 weeks (−42 days)of age) and subsequently injected with 20 mg/kg/week or vehiclecontinuing until either sacrifice at 95 days to analyze muscle mass, orend-stage as measured by right reflex failure.

Example 3.1.2: Body Weight and Muscle Mass Measurements

Initial body weights were used to evenly distribute animals amongcohorts so as to ensure equivalent average body weights at the start ofthe study. Onset of weight loss was scored as the age at which the firstof three consecutive measures of weight loss was observed. Wet musclemass was determined on the gastrocnemius, the cranial tibialis, thequadriceps, and the diaphragm at a point consistent with early disease(88 days for mice, 95 days for rats) and at end-stage (−134 days formice and −128 days for rats). Animals were euthanized and muscles fromeach leg were quantitatively dissected and weighed; values from rightand left legs were averaged.

Example 3.1.3: Muscle Histopathology and Motor Neuron Counts

Gastrocnemius and diaphragm were fixed and sectioned for H&E staining(Howland et al. (2002) Proc. Natl. Acad. Sci. U.S.A. 99:1604-29).Scoring for atrophy and hypertrophy was performed by two independentpathologists, blinded to sample identity. Fiber diameters were measuredby morphometry (Axiovision 4.3, Zeiss, Thornwood, N.Y.) on gastrocnemiusmuscle (PBS- and RK35-treated SODG93A mice and PBS-treated wild typemice) at 88 days and end-stage, as well as for diaphragm muscle (PBS-and RK35-treated SODG93A and PBS-treated wild type mice) and end-stage.Three muscles per group were snap frozen in dry-ice-cooled isopentane,cryosectioned at a thickness of 8 μm, and immunostained using ananti-laminin antibody (Sigma, St. Louis, Mo.; catalog number L9393).Linear measurements of the maximum diameter of the minor axis of atleast two hundred fibers were taken, using Zeiss Axiovision software.Fiber diameters were binned in 20 μm intervals, and frequency histogramswere generated for each muscle group.

Motor neuron counts were performed on 3 mice from each group (wild type,PBS-treated SODG93A, and RK35-treated SODG93A) at both early-stage andend-stage disease (total of 18 mice analyzed). Spinal columns removedfrom decapitated mice were post-fixed in 4% paraformaldehyde, then cordswere dissected and post-fixed for an additional 24 hours in 4%paraformaldehyde. Using MULTIBRAIN™ technology (Neuroscience Associates,Knoxville, Tenn.), 18 lumbar spinal cords were embedded together on asingle block, and cross-sectioned at 50 μm in the coronal plane alongthe entire segment (˜6 mm) of the lumbar enlargement. Every sixthsection (300 μm) was stained with thionine NISSL to reveal cell bodies(Bjugn (1993) Brain Res. 627:25-33; Kieran et al. (2004) Nat. Med.10:402-05). Counts were performed using two independent approaches.First, ten spinal cord sections encompassing L3-5 for each of 18 micewere analyzed by an observer blinded to sample identity using a ZeissAxioplan2 at 20× and 40×. Both ventral horns from each section werecounted, identifying large healthy motor neurons by the presence ofvisible nucleoli as described previously (Kieran et al., supra). Theresulting data were represented as the average number of large motorneurons per ventral horn. Second, sections from the L3-L5 region wereanalyzed stereologically using a Zeiss AXIOSKOP®2 equipped with amotorized specimen stage, electronic microcator, and stereology software(STEREO INVESTIGATOR® (MBF Bioscience, Williston, Vt.), as described(West et al. (1991) Anat. Rec. 231:482-97; Schmitz and Hof (2000) J.Chem. Neuroanat. 20:93-114; Schmitz and Hof (2005) Neuroscience130:813-31); α-motor neurons were scored as neurons with a maximumprojection area greater than 300 μm².

Example 3.1.4: Phenotypic Analysis

Grip strength measurements (Columbus Instruments, Columbus, Ohio) wereperformed biweekly starting 28 days after birth on both the front andhind limbs of treated and control mice (n=8-24) as described (LaMonte etal. (2002) Neuron 34:715-24). Transgenic and wild type rats were testedfor forelimb grip strength twice weekly using a Dunnett rat gripstrength meter (MJS Technology, Stevenage, Hertfordshire, England) inearly disease phase (between 95 and 110 days after birth; n=10). Ratswere also analyzed by rotorod (Ugo Basile, Comerio, Italy) as well asmonitored for abnormalities in gait and degrees of limb mobility (datanot shown).

Example 3.1.5: Electrophysiology

Electromyography (EMG) recordings and data analysis were performedblinded to genotype and treatment group. Nembutal-anesthetized ratsmaintained at 35-37° C. body temperature were subjected to needle EMG byinserting a concentric monopolar needle electrode (9013R0011, Medtronic,Minn., USA) into the surgically-exposed diaphragm muscle until bursts ofEMG interference pattern appeared with each inspiration. Electricalsignals were acquired at 20 KHz with a BIOPAC setup consisting of MP150Data Acquisition Unit, UIM100C Universal Interface Module, EMG100CElectromyography module, and the Acknowledge software (BIOPAC SystemsInc, Goleta, Calif.). The signals were first analyzed to remove 60 Hzartifact and band-pass filtered between 500 and 1000 Hz to removemovement artifacts due to breathing and to emphasize the motor-unitdischarges. EMG bursts were identified by rectifying the signal,low-pass filtering at 10 Hz, and then detecting the times at which theresulting envelope was greater than its mean value. Bursts that lastedless than 100 ms were not counted, and nonburst periods that lasted lessthan 100 ms were counted as parts of the surrounding bursts. Finally,the spikes in the nonrectified signal were detected using a peakdetection threshold set equal to three times the standard deviation ofthe signal amplitude during the nonburst periods. Spike burst analysiswas performed with custom software written by K. C. McGill (StanfordUniversity, CA), and the burst spike rate (Hz) for each animal computedas the mean number of spikes per burst divided by the mean burstduration.

Example 3.1.6: Data Analysis and Statistics

A two-factor-repeated measures ANOVA model was applied on body weightdata as well as all grip strength data using an SAS mixed procedure. Atwo-factor ANOVA linear model was applied on muscle mass data using theSAS GLM procedure. Electrophysiology data was analyzed by the two samplet-test. For motor neuron count data, a generalized linear model (GLM)assuming Poisson distribution was used. Muscle fiber data were analyzedby ANOVA followed by Tukey's multiple comparison test. Comparisons wereconsidered statistically significant when p values were less than 0.05;comparisons with 0.05<p<0.15 were noted as trends.

Example 3.2: Results Example 3.2.1: RK35 Treatment Increased BodyWeights of SODG93A Rodents but Did not Extend Survival

SODG93A mice were treated with the anti-myostatin antibody RK35 starting28 days after birth and continuing to end-stage disease (approximately134 days after birth). RK35 treatment resulted in significantlyincreased body weight from 40 to 120 days after birth compared toPBS-treated SODG93A mice. While PBS-treated SODG93A mice reached amaximum body weight of 27.78±0.46 g at 70 days, RK35-treated micereached a maximum of 32.13±0.48 g, a relative increase of 16% (FIG. 2A).While wild type mice continued to gain weight throughout the study, bothPBS- and RK35-treated SODG93A mice began to show significant signs ofweight loss due to disease progression approximately 98 days afterbirth.

Transgenic SODG93A rats were also treated with RK35 antibody starting 42days after birth and continuing to end-stage disease (˜128 days old).Treatment with anti-myostatin RK35 led to increased body weight inSODG93A rats compared to PBS-treated rats (FIG. 2B). Transgenic ratsreceiving RK35 weighed significantly more than PBS-treated transgenicrats as early as 60 days after birth (p<0.05), corresponding to 3 weeksafter initiation of dosing. RK35-treated male rats reached a maximum of458.8±6.5 g at 96 days, a 10% increase over PBS-treated male rats at419.1±10.7 g. RK35-treated females reached a maximum of 289.7±9.3 g, a15% increase over PBS-treated females at 252.8±6.0 g. SODG93A ratstreated with either PBS or RK35 began to show significant weight lossafter ˜112 days due to disease progression; RK35 treatment did not delaythe initiation of weight loss.

While RK35 treatment led to significant increases in body weight, theinventors observed no effects of RK35 treatment on survival. Time toend-stage, as measured using the defined endpoint of failure to rightwithin 30 seconds, was 132±8 days for RK35-treated SODG93A mice (n=16),while PBS-treated SODG93A mice reached end-stage by 134±7 days (n=17).SODG93A rats treated with RK35 reached end-stage by 125±8 days comparedto 128±6 days for PBS-treated SODG93A rats. None of these differenceswere statistically significant, indicating that inhibition of myostatindoes not delay time to end-stage disease in either mouse or rat modelsof ALS.

Example 3.2.2: Effects of Myostatin Inhibition on Muscle Mass andStrength

In order to determine whether myostatin inhibition slowed musclewasting, SODG93A transgenic and wild type mice from each group weresacrificed at 88 days after birth, a time point close to the maximumincrease in body weight induced by the RK35 treatment. At this timepoint, PBS-treated SODG93A mice show significant decreases in musclemass in the gastrocnemius, cranial tibialis, and quadriceps relative towild type control mice consistent with early-stage disease (FIG. 2C). Incontrast, RK35-treated SODG93A mice displayed statistically significantimprovements in muscle mass in all muscles examined in comparison toage-matched PBS-treated SODG93A mice at the 88-day time point rangingfrom ˜19% to 32% (gastrocnemius muscle, +26%; cranial tibialis, +19%;quadriceps, +32%). While no significant loss of muscle mass was observedin diaphragms from PBS-treated SODG93A mice during early-stage disease;RK35 treatment induced a significant increase in mass in this muscle aswell (+21%).

The remaining mice in each cohort were monitored until end-stage asdefined by the right reflex test. At end-stage, leg muscle wasting wasobserved in both RK35-treated and PBS-treated SODG93A mice (FIG. 2E). Incontrast to the observations on tissue from 88-day mice, at end-stagedisease PBS-treated SODG93A mice showed a significant reduction indiaphragm muscle mass relative to wild type animals (FIG. 2E). However,the RK35-induced increase in diaphragm mass observed in treated SODG93Amice remained significant at end-stage, indicating that myostatininhibition slowed atrophy of the diaphragm in the SODG93A mouse.

The effects of anti-myostatin antibody on muscle mass were alsoinvestigated in SODG93A rats. Similar to observations made in mice,˜95-day-old SODG93A rats treated with RK35 showed significantlyincreased mass over PBS-treated SODG93A rats in gastrocnemius (+17%),cranial tibialis (+30%), quadriceps (+30%) and diaphragm (+17%) muscles(FIG. 2D). By end-stage disease, leg muscle atrophy was apparent in bothPBS- and RK35-treated SODG93A rats (FIG. 2F). A trend toward increasedleg muscle mass as a result of RK35 treatment in the SODG93A ratspersisted to end-stage, but these effects did not reach significance.However, a robust and significant 35% increase in diaphragm mass fromRK35-treated SODG93A rats over PBS-treated controls (˜35%) was stillevident at end-stage disease (FIG. 2F), in agreement with theobservations seen with the SODG93A mice (FIG. 2E).

In order to test the effects of myostatin inhibition on muscle function,quantitative grip strength assays on RK35 and PBS-treated mice wereperformed. Both RK35-treated and PBS-treated SODG93A mice showeddevelopmental increases in hind limb grip strength between 28 and 56days after birth. By 56 days after birth, PBS-treated SODG93A micebecome significantly weaker than age-matched control mice (FIG. 3A)(p<0.0001). While declines in grip strength were also apparent inRK35-treated SODG93A mice by 63 days after birth, the RK35-treated miceremained significantly stronger (or tended toward stronger) thanPBS-treated SODG93A mice from 49 to 88 days after birth (p<0.05).Analysis of forelimb grip strength showed a similar pattern (FIG. 3B).Peak forelimb strength in both PBS- and RK35-treated SODG93A mice wasobserved by ˜49 and 56 days after birth, respectively. PBS-treatedSODG93A mice became significantly weaker than wild type animals by 56days after birth (p<0.05) and continued to decline thereafter.RK35-treated SODG93A mice were stronger than PBS-treated SODG93A micefrom 56 to 88 days in age (56 d; p=0.08; 63 d; p=0.06; 70-88 d;p<0.001). These data indicate that myostatin inhibition slows loss ofmuscle function through early-stage disease in the SODG93A mice.However, after ˜100 days, declines in grip strength were similar in bothtreated and untreated SODG93A mice.

To determine if RK35 treatment induced similar changes in SODG93A rats,forelimb grip strength was also analyzed in RK35 and PBS-treated SODG93Arats and age matched wild type littermates during early-stage disease(FIG. 3C). PBS-treated SODG93A rats were significantly weaker than wildtype controls, confirming that SODG93A rats also exhibit an earlydisease phase that precedes overt motor deficits and weight loss in amanner similar to mice. Grip strength measurements of RK35-treatedSODG93A rats were generally lower than those of PBS-treated wild typerats, although the groups were not significantly different. Myostatininhibition in SODG93A rats did significantly improve grip strength whencompared to PBS-treated SODG93A rats at this age interval.

Example 3.2.3: Myostatin Inhibition Slowed the Degeneration of LimbMuscles and Diaphragm in SODG93A Mice and Rats

The effects of RK35 treatment on muscle morphology were also examined.Diaphragm and medial gastrocnemius muscle from 88 day (early-stagedisease) and ˜134 day (end-stage disease) SODG93A mice were examined,comparing the effects of RK35 treatment with PBS, in parallel withtissue from age-matched wild type controls. The degree of atrophy andhypertrophy in each tissue was scored in a blinded analysis (0, none; 1,slight; 2, mild; 3, moderate; 4, marked; 5, severe) as shown in Table 4.PBS-treated SODG93A mice showed significant atrophy of gastrocnemius atearly-stage disease (mean score of 2.0; and FIG. 4B). The observedshrinkage of muscle fibers, centrally placed nuclei andchromatin-condensed nuclei were consistent with muscle undergoing activedenervation; there was also evidence of inflammation compared to wildtype mice (FIGS. 4A and B). In contrast, the gastrocnemius fromearly-stage SODG93A mice treated with RK35 (FIG. 4C) showed little to noatrophy (Table 4; mean score of 0.3). These results support the musclemass data indicating that atrophy of the skeletal leg muscle in earlyphase disease (88 days after birth) in the SODG93A mice is significantlyreduced by myostatin inhibition.

Examination of gastrocnemius from end-stage SODG93A mice confirmedmoderate muscle atrophy in both PBS (Table 4; mean score of 3.0) andRK35 treated (Table 4; mean score of 3.3) (FIGS. 4E and F) groups withno degenerative signs in wild type muscle (FIG. 4D). These results areconsistent with the muscle mass data, indicating that the protectiveeffects of myostatin inhibition in early disease do not persist throughend-stage disease in SODG93A mice.

The diaphragm from either PBS-treated or RK35-treated SODG93A miceshowed little to no atrophy (Table 4; mean scores of 0.6) compared towild type mice at 88 days. By end-stage, however, mild to moderateatrophy was observed in diaphragm from PBS-treated SODG93A mice (FIG.4H; Table 4; mean score of 2.3). In contrast, diaphragm fromRK35-treated SODG93A mice analyzed at end-stage disease showed nosignificant signs of atrophy compared to PBS-treated SODG93A animals(Table 4; compare FIGS. 4H and 4I), similar to diaphragm fromage-matched wild type mice (FIG. 4G). Taken together, the muscle massand histological assessment indicate that myostatin inhibition by RK35preserves diaphragm but not skeletal leg muscle integrity throughend-stage of disease.

TABLE 4 Summary of muscle pathology observed in SODG93A mice treatedwith PBS or RK35, in comparison with age-matched wild type control mice.genotype: G93A G93A WT G93A G93A WT RK35: − + − − + − Age: 88 d 88 d 88d 134 d 134 d 134 d # mice: 3 3 3 3 3 3 gastrocnemius hypertrophy 0 0 00 0 0 atrophy 2 0.3 0 3.0 3.3 0 diaphragm hypertrophy 0 0.6 0 0 1.7 0atrophy 0.6 0.6 0 2.3 0 0 Scoring: 0, none; 1, slight; 2, mild; 3,moderate; 4, marked; 5, severe

Analysis of muscle fiber size in gastrocnemius and diaphragm muscleshowed a similar pattern. Frequency distributions of fiber diametermeasurements from 88-day gastrocnemius muscle show a shift towardsmaller fibers in SODG93A mice (FIG. 5A) in comparison to wild typecontrol mice (FIG. 5C). The distribution of fiber diameters fromRK35-treated SODG93A mice (FIG. 5B) is intermediate between untreatedSODG93A mice and wild type mice during early-stage disease. Byend-stage, however, average fiber diameter in the gastrocnemius muscleof RK35-treated SODG93A mice did not differ significantly fromPBS-treated SODG93A mice (data not shown). Average fiber diameters inthe gastrocnemius muscle from both RK35-treated and PBS-treated SODG93Amice were significantly different than wild type at end-stage,consistent with the marked muscle atrophy observed by histology.Significant differences in fiber size between wild type and PBS-treatedSODG93A mice were also evident at end-stage in diaphragm muscle.Diaphragm muscle fiber size from RK35-treated SODG93A mice showed asignificant shift in average fiber diameter, leading to a sizedistribution intermediate between wild type and PBS-treated SODG93A mice(FIG. 5D).

The effects of SODG93A expression on the electrical activity of thediaphragm muscle (FIGS. 4J and 4K) were next examined using the ratmodel at a time corresponding to clinical onset (˜112 days; Howland etal. (2002) Proc. Natl. Acad. Sci. U.S.A. 99:1604-09). The EMG shown forthe PBS-treated SODG93A rat group shows sparse spike activity as well assome presence of abnormal spontaneous activity (FIG. 4J). Spike activityof SODG93A rats treated with RK35 was similar to that observed for wildtype rats, with no evidence of abnormal spontaneous activity. As shownin FIG. 4K, diaphragm muscle from transgenic SODG93A rats showed astatistically significant decrease in EMG burst spike rates indicativeof impaired function. In contrast, SODG93A rats treated with RK35 showeda burst spike rate that was significantly higher than the PBS-treatedSODG93A rats, and which was not significantly different from age-matchedwild type controls. Therefore, myostatin inhibition by RK35 waseffective in preserving both diaphragm structure and diaphragm function.

Example 3.2.4: Myostatin Inhibition Slows Loss of Motor Neurons in theVentral Horn

To determine whether RK35 slowed the loss of large motor neurons inspinal cord, large motor neurons in lumbar L3-5 mouse spinal cord fromSODG93A mice treated with RK35 or PBS and wild type mice treated withPBS were counted. Counts were performed on spinal cord at 12 weeks(84-90 days in age; mean of 88 days), a time when RK35 treatmentresulted in increased muscle mass, increased body weight, increased gripstrength and attenuated muscle histopathology in SODG93A mice. At thistime, there is significant loss (25-40%) of large motor neurons in theSODG93A mouse (Guo et al. (2003) Hum. Mol. Genet. 12:2519-32; Sharp(2005) Neuroscience 130:897-910; Schutz et al. (2005) J. Neurosci.25:7805-12).

Counts of large lumbar motor neurons (FIGS. 6A-D) in PBS-treated SODG93Amice (FIG. 6F) decreased significantly compared to littermate wild typecontrols (FIG. 6E). RK35 treatment reduced the loss of motor neurons atearly-stage disease (FIG. 6G) to a level intermediate betweenPBS-treated SODG93A mice and wild type mice.

By end-stage disease, significant losses of large motor neurons in thelumbar ventral horn as well as increased gliosis were evident in theSODG93A mice regardless of treatment (FIGS. 6I and J) with nocorresponding changes noted in wild type mice (FIG. 6H).

Stereological counting of the total population of large motor neurons(area greater than 300 μm²) revealed a trend of 25% motor neuron loss inPBS-treated SODG93A mice in comparison to wild type controls. A trendtoward a slowing of motor neuron loss was observed in mice treated withRK35 (p=0.08) (FIG. 6A). If counts were restricted to large motorneurons with visible nucleoli to avoid counting motor neurons showingsigns of degeneration (i.e., presence of irregular membrane andvacuoles), there is a 40% decrease in the average number of large motorneurons per section in PBS-treated SODG93A mice in comparison to wildtype control mice (FIG. 6B), as well as a statistically significantdifference between RK35-treated and PBS-treated SODG93A mice (FIG. 6B).Taken together, however, the composite data shown in FIGS. 6A and Bindicate that both the loss of large motor neurons and the effects ofRK35 treatment on this loss are relatively subtle at the 12-week (88day) age interval.

By end-stage, motor neuron counts in both RK35-treated and PBS-treatedSODG93A mice were significantly different from wild type control mice byboth methods of analysis (FIGS. 6C and D). These data are consistentwith data on skeletal muscle structure and function presented above thatthe RK35-mediated improvements observed during early-stage disease arenot maintained at end-stage.

Example 4 Discussion

ALS is a fatal and progressive disease in which motor neurons of thespinal cord and brain stem degenerate with subsequent muscle atrophy.Considerable attention has focused on mechanisms involved in motorneuron cell death. Several recent studies have suggested that multiplecell types may be involved in the etiology of the disease by controllingthe production of key factors in the extracellular microenvironment ofthe neuromuscular junction (Bruijn et al. (2004) Annu. Rev. Neurosci.27:723-49). Studies using chimeric mice have shown that the presence ofwild type nonneuronal cells can extend survival of motor neuronsexpressing mutant SOD1 (Clement et al. (2003) Science 302:113-17). Theseobservations have led to the investigation of therapies that might slowneuronal degeneration by providing an optimal microenvironment forsurvival. For example, administration into muscle of virally expressedgrowth factors including IGF-1, GDNF and VEGF have all been shown toprolong survival in the SODG93A mouse model (Kaspar et al. (2003)Science 301:839-42; Azzouz et al. (2004) Nature 429:413-17; Wang et al(2002) J. Neurosci. 22:6920-28). Furthermore, muscle-specific expressionof IGF-1 has been shown to stabilize neuromuscular junctions, enhancemotor neuron survival, and delay onset and progression of disease in theSODG93A transgenic mouse model, indicating that direct effects on musclecan impact disease onset and progression (Dobrowolny et al. (2005) J.Cell. Biol. 168:193-99). Changes in muscle metabolism and motor neuronvulnerability have also been reported in ALS mice, further supportingthe hypothesis that muscle may be an active driver of disease pathology(Dupois et al. (2004) Proc. Natl. Acad. Sci. USA 101:11159-64).

Myostatin, or GDF-8, is an endogenous inhibitor of muscle growth,eliciting its biological function, at least in part, by activation ofthe Activin lib receptor (ActRIIb), resulting in repression of myoblastcell proliferation and differentiation (Langley et al. (2002) J. Biol.Chem. 277:49831-40; Thomas et al. (2000) J. Biol. Chem. 275:40235-43).Inhibition of GDF-8 function using anti-GDF-8 neutralizing antibodieshas been shown to enhance muscle mass and strength in healthy adult miceas well as provide functional improvement in the mdx mouse model ofmuscular dystrophy (Whittemore et al. (2003) Biochem. Biophys. Res.Commun. 300:965-71; Bogdanovich et al. (2002) Nature 420:418-21). Tobetter understand the role of muscle in motor neuron diseaseprogression, a novel neutralizing antibody to GDF-8, RK35, which bindswith higher affinity than a previously described reagent (IC₅₀ 3 nM forRK35 vs. >100 nM for JA16; Whittemore et al. (2003) Biochem. Biophys.Res. Commun. 300:965-71; Bogdanovich et al. (2002) Nature 420:418-21)was used, resulting in greater increases in muscle mass in wild typemice treated with RK35 (data not shown).

In SODG93A mouse and rat models of familial ALS, treatment with RK35resulted in increased body weight and increased muscle mass and strengthduring the early phases of motor neuron disease. This early phase ofdisease is defined as the age (56-88 days after birth) at which SODG93Amice show a significant loss of muscle strength, as measured by gripstrength assessment (Ligon et al. (2005) Neuroreport 16:533-36) and gaitabnormalities (Wooley et al. (2005) Muscle Nerve 32:43-50), and whichcoincides with the denervation of neuromuscular junctions (Frey et al.(2000) J. Neurosci. 20:2534-42; Fischer et al (2004) ExperimentalNeurology 185:232-40). Muscle mass increases resulting from GDF-8inhibition by RK35 were most evident in the quadriceps muscles, but werealso pronounced in the gastrocnemius, cranial tibialis and the diaphragmin both rodent models tested. These increases correlated well withincreased strength, as hindlimb and forelimb strength declined moreslowly in RK35-treated mice in comparison to controls. The extent ofmuscle mass increase induced by treatment with the RK35 anti-GDF-8antibody was similar in magnitude to a 25% increase in muscle massobserved in mice heterozygous for disruption of the GDF-8 gene; musclemass from mice that are homozygous null for GDF-8 is about two-fold thatof wild type mice (McPherron (1997) Nature 387:83-90).

At approximately 84-88 days after birth in SODG93A mice, andapproximately 110 days for SODG93A rats, overt signs of diseaseincluding body weight decreases, gait abnormalities and paralysis becomeevident. RK35 treatment did not extend survival in either SODG93A miceor rats. The increased muscle mass and strength induced by anti-GDF-8treatment in the early phase of disease did not delay the appearance ofgait abnormalities and limb paralysis in both SODG93A mice and rats(data not shown), nor were gains in leg muscle mass maintained.

However, significant increases in diaphragm mass in RK35-treated SODG93Amice and rats as compared to vehicle-treated SODG93A controls in bothearly and end-stage disease phases were observed. Diaphragm muscle inRK35-treated SODG93A mice at end-stage was comparable to that ofage-matched wild type controls in both mass and histological evaluation.RK35-treated SODG93A rats also maintained a significant increase indiaphragm muscle mass at end-stage. Consistent with these morphologicalchanges, electrophysiological analysis of diaphragms from untreatedSODG93A rats indicates that expression of mutant SOD1 results insignificant inhibition of muscle function, and that treatment with RK35effectively preserved muscle function in the diaphragm.

In this study a defined endpoint (failure of the right reflex test,indicating significant limb paralysis) was used, as the criteria for“end-stage” and euthanasia. Therefore it is not clear whether theenhanced diaphragm muscle mass, decreased atrophy, and improvedelectrophysiological function induced by RK35 treatment would haveresulted in prolonged lifespan in rodents provided with nutritionalsupplementation. However, these findings are potentially important giventhe fact that respiratory dysfunction is the leading cause of death inpatients with ALS (Lechtzin et al. (2002) Amyotroph. Lateral Scler.Other Motor Neuron Disord. 3:5-13). Treatments such as RK35 designed toenhance diaphragm function may have the potential to delay the necessityfor mechanically assisted breathing in ALS patients.

GDF-8 inhibition by RK35 may influence motor neuron loss in the lumbarspinal cord in the early disease phase, although many therapeuticbenefits apparently were lost by end-stage disease. These data indicatethat therapies acting directly on muscle can have a benefit on motorneurons innervating muscle, possibly by modulating the trophicmicroenvironment, although this approach is apparently not sufficient todelay disease. These observations are therefore consistent with theresults of Dobrowolny et al. ((2005) J. Cell. Biol. 168:193-99), inwhich expression of a muscle-specific isoform of IGF led to slowed lossof motor neurons in the SODG93A mouse model, and that of Kaspar et al.((2003) Science 301:839-42), where viral delivery of IGF1 to muscleresulted in reduced motor neuron loss in early-stage disease. Similar tothe observations of Kaspar et al. ((2003), supra), beneficial effects oftreatment on motor neuron survival were not maintained through end-stagedisease. Improved trophic factor support from muscle is therefore likelyto be insufficient to prevent motor neuron loss in the SODG93A model.

In summary, in both mouse and rat models of familial ALS, inhibition ofmyostatin results in enhanced muscle mass and strength, which ismaintained through the early stages of disease but lost by end-stage.Myostatin inhibition slowed degenerative changes in skeletal muscle inearly-stage disease, but did not delay onset of paralysis nor extendsurvival, as defined by right reflex failure, nor did myostatininhibition significantly slow motor neuron loss. However, bothmorphological and functional differences through late-stage disease wereobserved in the diaphragm muscle of animals treated with anti-myostatinantibody, in comparison to untreated controls. Overall, the dataprovided herein support the potential for a beneficial effect of musclebuilding by treatment with RK35, which may contribute to an enhanced“quality of patient life” early in the disease process. Given thatanti-GDF-8 antibodies are currently in clinical development, use of suchclinical reagents in ALS for the maintenance of limb and diaphragmmuscle mass warrants further investigation as a component of amulti-pronged approach to the treatment of ALS. The combination of ananti-GDF-8 therapy with existing drugs such as the glutamate-antagonistriluzole, or newer agents entering clinical development, might not onlyimprove the level of efficacy by helping maintain muscle mass but alsohave significant impact on overall patient quality of life.

Example 5 Mapping of Epitopes for RK35

In order to map the exact antibody epitopes to GDF-8, 48 overlapping13-residue peptides representing the entire sequence of mature GDF-8 setforth in SEQ ID NO:1 were synthesized directly on cellulose paper usingthe spot synthesis technique (e.g., Molina et al. (1996) Peptide Res.9:151-55; Frank et al. (1992) Tetrahedron 48:9217-32). The overlap ofthe peptides was 11 amino acids. In this array, cysteine residues werereplaced with serine in order to reduce the chemical complicationscaused by cysteines. Cellulose membranes modified with polyethyleneglycol and Fmoc-protected amino acids were purchased from Abimed(Lagenfeld, Germany). The array was defined on the membrane by couplinga β-alanine spacer, and peptides were synthesized using standard DIC(diisopropylcarbodiimide)/HOBt (hydroxybenzotriazole) coupling chemistryas described previously (Molina et al., supra; Frank et al., supra).

Activated amino acids were spotted using an Abimed ASP 222 robot.Washing and deprotection steps were done manually, and the peptides wereN-terminally acetylated after the final synthesis cycle. Followingpeptide synthesis, the membrane was washed in methanol for 10 minutesand in blocker (TBST (Tris-buffered saline with 0.1% (v/v) TWEEN™ 20)and 1% (w/v) casein) for 10 minutes. The membrane was then incubatedwith 2.5 μg/ml of an anti-GDF-8 antibody in blocker for 1 hr with gentleshaking After washing in blocker 3 times for 10 min, the membrane wasincubated with HRP-labeled secondary antibody (0.25 μg/ml in blocker)for 30 min. The membrane was then washed three times for 10 min eachwith blocker and 2 times for 10 minutes each with TBST. Bound antibodywas visualized using SUPERSIGNAL™ West reagent (Pierce; Rockford, Ill.)and a digital camera (Alpha Innotech Fluorimager (Alpha Innotech; SanLeandro, Calif.)). As shown in FIG. 7, the RK35 epitope maps to a regionof GDF-8 between amino acids 30-40 and 84-97, that putatively interactswith the GDF-8 Type II receptor as predicted by GDF-8 receptor sequencecomparison with homologous TGF-β family receptors with characterizeddomains.

Example 6 Characterizing the RK35 Antibody

The variable heavy (VH) and variable light (VL) genes encoding RK35 werecloned from hybridoma cells producing the antibody, and the amino acidsequences were determined. Sequence data for the RK35 antibody was usedto identify the nearest germline sequence for the heavy and light chain.A comparison of RK35 light and heavy variable regions with the closesthuman germline sequences is shown in FIG. 8. Appropriate mutations maybe made using standard site-directed mutagenesis techniques with theappropriate mutagenic primers. Mutation of the antibody is thenconfirmed by sequence analysis. Exemplary amino acid sequences forhumanized RK35 are set forth in SEQ ID NOs:7 (VH) and 9 (VL), both ofwhich may be encoded by a nucleic acid sequence readily determined by askilled artisan, e.g., the nucleic acid sequences set forth as SEQ IDNO:6 (VH) and 8 (VL). A skilled artisan will recognize that any and/orall amino acids in the framework of the humanized antibody may bemutated back to the original murine amino acid, e.g., to maintain theconformation of the antigen binding fragment. Nonlimiting examples ofSEQ ID NO:7 (VH) and SEQ ID NO:9 (VL) with some back-mutations that mayhelp to maintain the affinity of the antibody to GDF-8 are set forth asSEQ ID NO:26 and SEQ ID NO:27, respectively.

To create chimeric antibodies, the VH sequence is subcloned into a pED6huIgG1 mut expression vector, which encodes human IgG1 containing twopoint mutations (L234A and G237A) to reduce binding to human Fcreceptors and complement components (Morgan et al. (1995) Immunology86:319-24; Shields et al (2001) J. Biol. Chem. 276:6591-604). The VLsequence of RK35 may be subcloned into the pED6 Kappa expression vector.The expression vectors containing the RK35 VH and VL sequences are thencotransfected into COS-1 cells and a chimeric RK35 antibody is purifiedfrom conditioned medium.

Example 7 Treatment of Muscle Disorders

Inhibitors of GDF-8, i.e., GDF-8 antagonists, such as, for example,inhibitory antibodies, are useful for treatment of metabolic disordersassociated with GDF-8 such as type 2 diabetes, impaired glucosetolerance, metabolic syndrome (e.g., syndrome X), insulin resistance(e.g., induced by trauma such as burns or nitrogen imbalance), andadipose tissue disorders (e.g., obesity) Inhibitors of GDF-8 are alsouseful for the treatment of bone and muscle disorders associated withGDF-8, such as ALS, muscular dystrophy and osteoarthritis. Theanti-GDF-8 antibodies and antibody fragments of the invention may beused to treat a subject, e.g., a human subject, preferably a subjectsuffering from ALS, at disease onset, or a subject having an establishedmetabolic or bone/muscular disease. The inhibitory antibodies againstGDF-8 may also be used to prevent and/or to reduce the severity and/orthe symptoms of the disease. It is anticipated that the anti-GDF-8antibodies and antibody fragments are administered, e.g.,subcutaneously, as frequently as once per day and as infrequently asonce per month. Treatment durations range from about one month (or less)to several years.

To test the clinical efficacy of anti-GDF-8 in humans, subjectssuffering from or at risk for ALS are identified and randomized totreatment groups. Treatment groups include a placebo group and one tothree or more groups receiving antibody (at different doses when thereare two or more groups). Individuals are followed prospectively for,e.g., one month to three years to assess changes in weight, muscle mass,and grip strength. It is anticipated that individuals receivingtreatment will exhibit an improvement.

A GDF-8 antagonist, preferably in the form of an antibody or antibodies,is administered as the sole active compound or in combination withanother compound or composition. When administered as the sole activecompound or in combination with another compound or composition, thedosage is preferably from approximately 1 μg/kg to 100 mg/kg, dependingon the severity of the symptoms and/or the progression of the disease.The appropriate effective dose may be selected by a treating clinicianfrom the following nonlimiting list of ranges: 1 μg/kg to 100 mg/kg, 1μg/kg to 50 mg/kg, 1 μg/kg to 20 mg/kg, 1 μg/kg to 10 mg/kg, 1 μg/kg to1 mg/kg, 10 μg/kg to 1 mg/kg, 10 μg/kg to 100 μg/kg, 100 μg to 1 mg/kg,and 500 mg/kg to 1 mg/kg. Exemplary nonlimiting treatment regimens andpotential outcomes are summarized in Table 5.

TABLE 5 Examples of Potential Clinical Cases Status prior to Treatmenttreatment Regimen Potential Outcome No clinical signs, 0.01-1 mg/kgevery Prevention of ALS or family history of 4 weeks for 48 weeks delayof onset ALS Mild clinical signs 0.01-100 mg/kg weekly Improved grip ofALS for 4 or more weeks strength, weight gain, and muscle mass Advancedstage of 0.01-100 mg/kg twice Improvement of ALS characterized weeklyfor 6 or more clinical signs, by severe muscle weeks reduction inseverity wasting, weight of symptoms and/or loss, and loss of increasein muscle strength, etc. mass/body fat ratio

The specification is most thoroughly understood in light of theteachings of the references cited within the specification, all of whichare hereby incorporated by reference herein in their entireties. Theembodiments within the specification provide illustrations of theinvention and should not be construed to limit the scope of theinvention. The skilled artisan recognizes that many other embodimentsare encompassed by the claimed invention, and that the specification andexamples should be considered as exemplary only.

What is claimed is:
 1. A method of treating muscle wasting syndrome in amammal, comprising administering to a mammal in need of treatment formuscle wasting syndrome a therapeutically effective amount of a GDF-8specific antibody or antigen binding fragment thereof, said antibody orfragment comprising: an antibody variable heavy (VH) region comprisingthe first, second and third complementarity determining regions (CDR)from the VH region defined by the amino acid sequence of SEQ ID NO:3 orSEQ ID NO:7; and an antibody variable light (VL) region comprising thefirst, second and third complementarity determining regions (CDR) fromthe VL region defined by the amino acid sequence of SEQ ID NO:5 or SEQID NO:9.
 2. The method of claim 1, wherein VH CDR1 comprises SEQ IDNO:10 or SEQ ID NO:20, VH CDR2 comprises SEQ ID NO:11 or SEQ ID NO:21,VH CDR3 comprises SEQ ID NO:12, VL CDR1 comprises SEQ ID NO:13, VL CDR2comprises SEQ ID NO:14, and VL CDR3 comprises SEQ ID NO:15.
 3. Themethod of claim 1, wherein the VH region of said antibody or fragmentcomprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7.
 4. Themethod of claim 1, wherein the VL region of said antibody or fragmentcomprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:9.
 5. Themethod of claim 1, wherein the VH region of said antibody or fragmentcomprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7 and theVL region of said antibody or fragment comprises the amino acid sequenceof SEQ ID NO:5 or SEQ ID NO:9.
 6. The method of claim 1, wherein the VHregion of said antibody or fragment comprises the amino acid sequence ofSEQ ID NO:7 and the VL region of said antibody or fragment comprises theamino acid sequence of SEQ ID NO:9.
 7. The method of claim 1, whereinsaid antibody or fragment is partially or fully humanized.
 8. The methodof claim 1, wherein said antibody binds to GDF-8 with an affinity ofabout 10 nM or higher affinity.
 9. The method fragment of claim 1,wherein said fragment is selected from the group consisting of an Fdfragment, an Fab fragment, an F(ab′)2 fragment, an scFv fragment, and anFv fragment.
 10. The method of claim 1, wherein said antibody orfragment further comprises an antibody constant heavy region from ahuman immunoglobulin subtype selected from the group consisting IgG1,IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE and IgM.
 11. The method orfragment of claim 10, wherein the antibody constant heavy region is fromhuman IgG1.
 12. The method of claim 10, wherein the constant heavyregion of said antibody or fragment is modified to alter a constantregion effector function.
 13. The method of claim 11, wherein saidconstant heavy region comprises the amino acid sequence of SEQ ID NO:19.14. The method of claim 13, wherein the amino acid sequence of SEQ IDNO:19 is modified at one or more residues altering a constant heavyregion effector function.
 15. The method of claim 13, wherein the aminoacid sequence of SEQ ID NO:19 is modified at least at residue 117 or 120thereof to alter an Fc region effector function.
 16. The method of claim1, wherein said antibody or fragment further comprises a human antibodykappa or lambda constant light region.
 17. The method of claim 16,wherein said constant light region comprises the amino acid sequence ofSEQ ID NO:17.
 18. A method of treating muscle wasting syndrome in amammal, comprising administering to a mammal in need of treatment formuscle wasting syndrome a therapeutically effective amount of a GDF-8specific antibody comprising: two antibody heavy chains, each comprisinga variable heavy region defined by the amino acid sequence of SEQ IDNO:7 and the constant heavy region from human IgG1; and two antibodylight chains, each comprising a variable light region defined by theamino acid sequence of SEQ ID NO:9 and a constant light region definedby the amino acid sequence of SEQ ID NO:17.
 19. The method of claim 18,wherein said constant heavy region comprises the amino acid sequence ofSEQ ID NO:19 modified at least at residue 117 or 120 thereof to alter anFc region effector function.